

# Changes in breathing reserve and expiratory flow limitation at peak exercise intensity after a 10-weeks exercise intervention in adolescents with asthma

Anette Nielsen



Masteroppgave ved Institutt for helse og samfunn,  
Medisinsk fakultet

Universitet i Oslo

Våren 2019

## **Preface/Acknowledgements**

*Dear dad. When you were alive, you inspired me to chase my dreams. You still do, even though you are not among us anymore. Thanks for being a loving, funny, kind, inspiring and encouraging dad, which I have many good memories from. Dear mum, little sister, brother-in-law, and boyfriend. Thank you all for being so supportive, understanding, caring, loving, funny and making me feel loved.*

*Thanks, Thomas Westergren, my main supervisor. Thank you for being positive, including and encouraging. Thanks for all the constructive, and concrete feedback and being flexible and available all the time! Thanks, Julie Stang, my bi-supervisor, which have been helpful with constructive and concrete feedback through the last part of the master thesis work, teaching me procedures at the respiratory physiological lab and for being including and inspiring.*

*Thank you, Oddbjørn Andersen, Svein Leirstein, Kristine R. Tufte, and Trine Stensrud at the Norwegian School of Sport Science. Thank you, Oddbjørn and Trine for stepping in when needed. Thanks, Oddbjørn for supervising us with the equipment and helping us. Thank you, Svein, for teaching me lab procedures and, helping with technical equipment. Kristine R. Tufte, you have been helpful with recruiting, in the data collection and plotting of data. Also, you are kind and funny! Thank you, Joakim Sigdestad for all your help with the project.*

*Thanks to all of our participants and your parents. Thank you for giving your time and energy on this project.*

*Thanks to neighbor Øystein Espedal for grammar correction and technical help! I appreciate your grammatical knowledge, kindness and for helping me on short notice.*

*Working with the master thesis and with Physical Activity and Asthma in Youth (PLAY) has been a challenging, but also an enriching process in my life. I have appreciated being part of several stages in the process.*

© Anette Nielsen

2019

Changes in breathing reserve and expiratory flow limitation at peak exercise intensity after a 10-week exercise intervention in adolescents with asthma

Anette

<http://www.duo.uio.no/>

Trykk: Reprosentralen, Universitetet i Oslo

# Table of contents

|       |  |    |
|-------|--|----|
| 1     | Part 1 Introductory review.....  | 1  |
| 1.1   | Sammendrag .....   | 1  |
| 1.2   | Abstract.....  | 2  |
| 2.0   | Introduction .....   | 4  |
| 2.1   | Structure of the article-based master thesis with an introductory review .....   | 4  |
| 2.2   | Why assessment of expiratory flow limitation and breathing reserve at peak oxygen uptake in adolescents with asthma is necessary ..... | 4  |
| 2.3   | Aim of this study .....  | 6  |
| 2.4   | Research question.....   | 6  |
| 2.5   | Priori hypothesis.....   | 6  |
| 3.0   | Theoretical background.....  | 7  |
| 3.1   | Ventilatory function .....   | 7  |
| 3.1.1 | Cardiopulmonary variables measured during exercise .....   | 7  |
| 3.1.2 | Measurement of lung function .....   | 8  |
| 3.1.3 | Measurement of maximal voluntary ventilation and BR .....  | 8  |
| 3.1.4 | Measurement of EFL.....  | 8  |
| 3.2   | Ventilation during exercise in without having asthma.....  | 9  |
| 3.3   | Ventilation during exercise while having asthma .....  | 9  |
| 3.4   | Previous research on exercise and bronchial hyperresponsiveness .....  | 11 |
| 4.0   | Extended discussion: .....   | 11 |
| 4.1   | Statistical considerations .....   | 11 |
| 4.2   | Reliability and validity of the measurement of extFVL/MFVL-analysis during exercise  |    |
| 12    |  |    |
| 4.3   | Reliability and validity of methods of calculating BR .....  | 13 |
| 4.4   | Strength and limitations of the study.....   | 14 |

|   |    |
|---|----|
| 4.5 Ethical considerations .....  | 16 |
| 4.6 Future research .....   | 18 |
| 5.0 References .....  | 19 |
| Part 2: Changes in breathing reserve and expiratory flow limitation at peak exercise intensity<br>after a 10-week exercise intervention in adolescents with asthma..... | 23 |
| Part 3 Appendices for the master thesis .....   | 42 |
| Appendix 1: List of abbreviations .....   | 42 |
| Appendix 2a: Information letter of consent and consent form, for parents: .....   | 43 |
| Appendix 4: Figures and tables for the introductory review .....  | 52 |
| Appendix 5: Submission guidelines for BMJ Open Respiratory Research .....   | 54 |
| Appendix 6: Permission to use figures:.....   | 60 |

# 1 Part 1 Introductory review

## 1.1 Sammendrag

**Formål:** Denne masteroppgaven har som hensikt å se på i hvilken grad pustereserve og luftstrømsobstruksjon ved maksimal belastning hos ungdommer med astma forandrer seg fra før til etter en treningsintervensjon. **Teoretisk forankring:** Trening kan være bra for ungdom med astma med tanke på psykososial funksjon, livskvalitet og kardiorespiratorisk form. Imidlertid gir også ungdommer med astma uttrykk for å oppleve pustebegrensninger under trening, og at pustebegrensningene kan hindre dem i trening. Det er imidlertid begrenset kunnskap om hvordan pustemekanismen fungerer under maksimal belastning. **Metode:** 15 ungdommer (13-18 år) med astma gjennomførte en 10 ukers treningsintervensjon med varierte kondisjonsaktiviteter. Oppmøte og pulsregistrering fra hver treningsøktene ble registrert. Deltakerne ble testet før og etter intervensjonen på laboratoriet. Lungefunksjon ble målt med spirometri. Peak oksygenopptak ( $VO_{2peak}$ ) ble målt under en kardiopulmonal belastningstest (CPET) på tredemølle. I tillegg ble intrabreath (IB)-målinger målt under  $VO_{2peak}$ . Graden av luftstrømsobstruksjon (EFL) ble definert ut ifra der hvor tidevolumet (extFVL) møter eller overstiger den forserte ekspiratorisk kurven (MFVL) fra hvile. Grunnet skjevfordelte data, ble en ikke-parametrisk statistisk test (Wilcoxon) brukt for å sjekke endring i variablene fra før til etter treningsintervensjonen. Spearman's rho ble brukt for å regne ut korrelasjon mellom variablene. Resultater er presentert som median med interkvartil bredde (IQR). **Resultater:** Luftstrømsobstruksjon hos ungdommene med astma var før treningsintervensjonen 0.0 % (23) og 0.0 % (0.0) etter treningsintervensjonen. Pustereserven hos ungdommene med astma var -0.6 % (15.6) før og 0.5 % (13.2) etter intervensjonen.  $VO_{2peak}$  var 39 ml/kg/l/min (16.2) hos ungdommene med astma før treningsintervensjon og 42.6 ml/kg/min (19.5) etter treningsintervensjonen. Negativ korrelasjon mellom pustereserve på  $\rho = -0.4$ ) og luftstrømsobstruksjon ble funnet, samt negativ korrelasjon mellom luftstrømsobstruksjon og  $VO_{2peak}$  ( $\rho = -0.4$ ). Peak minuttvolum ( $VE_{peak}$ ) hadde en korrelasjon på  $\rho = 0.1$  med luftstrømsobstruksjon. Pustereserven og  $VE_{peak}$  hadde en korrelasjon på  $\rho = 0.3$ . Alle korrelasjonsverdiene var ikke-signifikante. **Konklusjon:** Det kan tyde på at ungdommene med astma ikke har luftstrømsobstruksjon, og at de fortsatt har lav pustereserve, etter 10 ukers treningsintervensjon.

**Nøkkelord:** Astma, trening, pustebegrensning, luftstrømsobstruksjon, pustereserve, ungdommer, kardiopulmonær belastningstest

## 1.2 Abstract

**Purpose:** The aim of the study is to assess to what extent the breathing reserve (BR) and expiratory flow limitation (EFL) at peak exercise measured at peak oxygen uptake ( $VO_{2peak}$ ) change after an exercise intervention when compared with the baseline assessment in adolescents with asthma. **Literature framework:** Exercise is safe and beneficial for youth with asthma, in relation to psychosocial functioning, quality of life, and cardiorespiratory fitness. However, we also know that adolescents with asthma experience perceived breathlessness and dyspnea during exercise. There are few studies which investigate the ventilatory changes in adolescents with asthma at  $VO_{2peak}$ . **Method:** Fifteen children, aged 13-18 years, participated in an exercise intervention with various endurance activities for ten weeks. The data analyses included pre- and post-testing, attendance rate, and HR-monitoring during each session. Significance of variables before and after the exercise intervention was calculated by using Wilcoxon and correlation was checked using Spearman's rho due to skewed data. Results are presented as median with interquartile range unless otherwise stated (IQR). **Results:** There was no change in EFL from before (0.0 % [23]) to (0.0 % [0.0]) at post-assessment. BR was -0.6 % (15.6) before and -0.5 % (13.2) at post-assessment. Peak oxygen uptake ( $VO_{2peak}$ ) was (39 ml/kg/min [16.2] before to (42.6 ml/kg/min [19.5]) at post-assessment. There was a negative correlation of  $\rho=-0.4$  between BR and  $VO_{2peak}$  at post-assessment.  $VO_{2peak}$  showed also a negative correlation with EFL of  $\rho=0.4$  at post-assessment. Minute volume (VE) showed a correlation of  $\rho=0.1$  with EFL while BR and  $VE_{peak}$  had a correlation of  $\rho=0.3$ . All correlation values were non-significant at the post-assessment. **Conclusion:** The findings indicate that there is no EFL before or after and that BR remains low after the 10-week exercise intervention, in adolescents with asthma at  $VO_{2peak}$ .

**Keywords:** Asthma, exercise, ventilatory limitations, expiratory flow limitation, breathing reserve, extFVL/MFVL-analysis, exercise physiology, cardiopulmonary exercise testing

### Abbreviations

**EFL:** Expiratory flow limitation

**BR:** Breathing reserve

**PA:** Physical activity

**BHR:** Bronchial hyperresponsiveness

**EIB:** Exercise-induced bronchoconstriction

**extFVL:** tidal exercise flow-volume loop

**MFVL:** maximal flow-volume loop **CPET:** Cardiopulmonary exercise test

**VE:** Minute ventilation

**MVV:** Maximal voluntary ventilation

**FEV<sub>1</sub>:** Forced expiratory volume in 1 second

**FVC:** Forced vital capacity

**BF:** Breathing frequency

**VC:** vital capacity

**VE:** minute ventilation

**VO<sub>2</sub>:** oxygen uptake

**VO<sub>2-peak</sub>:** Highest VO<sub>2</sub> achieved on a test performed to limit tolerance

**VE/VCO<sub>2</sub>:** Ventilatory equivalent for VCO<sub>2</sub>

**VT:** tidal volume

**EILV:** End- inspiratory lung volume

**EELV:** End-expiratory lung volume

**IC:** inspiratory capacity



**ATS:** American Thoracic Society

**ICON:** International consensus on Pediatric Asthma

## **2.0 Introduction**

### **2.1 Structure of the article-based master thesis with an introductory review**

The thesis is comprised of three parts. Presented first (part 1) is the introductory review, which expounds on the theme, aim, research questions, hypothesis and relevance of the study within health research. Strength and limitations of this study as well as statistical and ethical consideration will also be further explained here. In part 2, the article written for publication in BMJ Open Respiratory Research follows. Note that the presented article is subject to further editing and does not necessarily represent the final version for submission. Also, note that the presented co-authors in the article version are presented along as if the article was sent in already. The result will only be presented in the following article. There, results will be analyzed together with the earlier theory and research in the discussion chapter, followed by the conclusion. Figures follow the reference list for the article, in line with submission guidelines for the journal. Last, several appendices relevant to the introductory review follow (part 3).

### **2.2 Why assessment of expiratory flow limitation and breathing reserve at peak oxygen uptake in adolescents with asthma is necessary**

According to the international consensus on pediatric asthma, (ICON) asthma can be defined as

[...] a chronic inflammatory disorder associated with variable airflow obstruction and bronchial hyperresponsiveness (BHR). It presents with recurrent episodes of wheeze, cough, shortness of breath and chest tightness (1, p. 33).

Currently, there is no nationwide study of the prevalence of asthma in Norway (2). However, in a cohort with children from Oslo, 20 % had asthma around 10 years of age. The prevalence of asthma increased to 26 % around 16 years of age (3,4). Asthma in childhood is a heterogeneous disease with different and variable symptoms depending on the age, gender, genetic background and environmental influences of the patient. Hence, several mechanisms can influence and trigger asthma (5).

One aim of treatment to achieve control of the disease is to use the least possible amount of medication (1). If asthma control is not achieved after controlling for medication compliance, environmental control, treatment for comorbid rhinitis, etc, stepping up medication should be considered (1). In addition to medical treatment, avoiding triggers for the disease can have beneficial effects on the activity of the disease. However, completely avoiding all allergens is usually impractical or impossible, and may have the added disadvantage of limiting the patient in daily life (1). Exercise has been shown to be useful for supplementary treatment of asthma (6). However, exercise can also trigger asthma; so-called exercise-induced bronchoconstriction (EIB) (7). EIB usually occurs a few minutes after exercise. It is defined as reversible narrowing of the airway, resulting in shortness of breath (8). EIB can be used to measure the BHR and can be a marker of asthma before the clinical diagnosis of asthma has been made (9). According to the American Thoracic Society (ATS) guidelines, EIB is defined as a drop of  $\geq 10\%$  in  $FEV_1$  after exertion on an exercise test (10). EIB occurs more often in children and adolescents (7). In a global perspective, EIB and exertional dyspnea occur in 9% of children and adolescents (11).

Symptoms of asthma can be one of the barriers to physical activity (PA) due to avoiding dyspnea, breathlessness in exercise, and are affecting more and more children and adolescents as the prevalence of asthma increases (7,12). According to Del Giacco, Firinu, Bjermer et al., there is a tendency for low participation in PA and physical play in children with asthma, which could have the possible consequence of negatively impacting the daily life quality in those children (7). People with asthma tend to report that they are symptomatically better when fit, however, the physiological basis of dyspnea has not been systematically investigated

yet (13). How expiratory flow limitation (EFL) influences exercise or contribute to perceived dyspnea is unclear (14). When defining and quantifying EFL, the constraint can be defined in degrees of limitation such as no or minimal, mild, moderate or severe limitation, rather than all-or-nothing phenomena (11). Reduced breathing reserve (BR) ( $<15\%$ ) at peak oxygen uptake ( $VO_{2peak}$ ) can also indicate a ventilatory limitation in adolescents but can also indicate that they use more of their ventilatory capacity (VC) (15). Whether BR in adolescents with asthma contribute to exercise limitation remains unclear.

Concerning ventilatory changes at maximal exertion, few studies have examined this, especially how BR and EFL at peak oxygen uptake ( $VO_{2peak}$ ) change in adolescents with asthma before to after an exercise intervention. Through assessing changes in EFL and BR, one can assess how these contribute to ventilatory limitation during exercise (14). According to ICON, there is a need for adjusting the recommendations for physical activity in the asthmatic treatment of the pediatric age group (1).

## **2.3 Aim of this study**

The aim of this study is to assess EFL and BR at  $VO_{2peak}$  before and after a 10-week exercise intervention in adolescents with asthma.

## **2.4 Research question**

The research question is:

- to which extent do BR and EFL at  $VO_{2peak}$  change after 10-week exercise intervention in adolescents with asthma compared with baseline assessment?

## **2.5 Priori hypothesis**

$H_0$ : There are no changes in BR and/or EFL under  $VO_{2peak}$  at post-test compared by baseline assessment

H<sub>1</sub>: There are changes in BR and/or EFL at VO<sub>2peak</sub> at post-test, compared by baseline assessment.

## **3.0 Theoretical background**

### **3.1 Ventilatory function**

Ventilation is the process that provides oxygen (O<sub>2</sub>) to the tissues in the body and removes carbon dioxide (CO<sub>2</sub>) from the body. The body and its cells need a steady supply of O<sub>2</sub> to survive and work. Ventilation is also needed to remove CO<sub>2</sub> from the body since CO<sub>2</sub> is a waste product of the metabolic process. Expiration means breathing out, while inspiration means breathing in (16).

#### **3.1.1 Cardiopulmonary variables measured during exercise**

Whether or not a persons ventilatory or cardiological functions are limited during exercise, can be measured during a cardiopulmonary exercise test (CPET) (15). CPET is an ergospirometric test with measurement of gas exchange; oxygen uptake (VO<sub>2</sub>) and carbon dioxide (VCO<sub>2</sub>) in expired air. CPET can be performed on a treadmill or an ergometer cycle. It is common to use test protocols with gradually increasing effort and lasting 8-12 minutes. The treadmill is motor-driven and introduces progressively increasing stress on the individual as the speed and incline of the treadmill rises (10).

The frequency of breathing per minute is called the breathing frequency (BF). The volume of expired air from the lungs during one minute is called the minute ventilation(VE), while the volume of air that is inspired or expired of each breath is called the tidal volume (VT). The volume expired from a maximal inspiration is called the vital capacity (VC) (10). Inspiratory capacity (IC) is the volume of air a person maximally can inspire when the person fully inspires with no stop after passive expiration(17). End-expiratory lung volume (EELV), is the volume of air remaining of the expired breath of the end the VT. The volume of air that is filling the lungs, is called the end-inspiratory lung volume (EILV) (10,11). The ratio of VE to VCO<sub>2</sub> is called the ventilatory equivalent for CO<sub>2</sub> (VE/VCO<sub>2</sub>) (10).

$\text{VO}_{2\text{-peak}}$  is the highest volume of oxygen uptake that the subject has performed to the limit of tolerance.  $\text{VO}_{2\text{-peak}}$  is expressed in liters per minute and is often adjusted for body weight (12). Help criteria such as plateauing of  $\text{VO}_{2\text{peak}}$ , achieved maximum heart rate, and a Borg Scale  $>17$ , and values over 1.15 are more likely to associated with maximum effort (10).

### **3.1.2 Measurement of lung function**

The forced expiratory capacity (FVC) is the volume of air that can be forcibly expired after a full inspiration.  $\text{FEV}_1$  is an abbreviation for the forced expiratory volume in one second, which is the volume of air expiration of the first second of the FVC-maneuver (10,17). FVC and  $\text{FEV}_1$  can be expressed in absolute values and given in liters, or as a percentage of predicted values, which are corrected for sex, age, height, and ethnicity(10,17-18). The  $\text{FEV}_1/\text{FVC}$  ratio represents how much of the persons vital capacity they are able to expire in the first second of forced expiratory expiration ( $\text{FEV}_1$ ) to the full forced vital capacity (19) Both  $\text{FEV}_1$  and FVC are measured using spirometry and at rest (17).

### **3.1.3 Measurement of maximal voluntary ventilation and BR**

The maximal volume of air that the person can breathe is called the maximal voluntary ventilation (MVV). According to the American Thoracic Society (ATS), MVV can be measured either directly for 10 seconds expressed in units of liters per minute or estimated by multiplying  $\text{FEV}_1$  with 35 (10). MVV can be used to calculate BR at  $\text{VO}_{2\text{peak}}$ . When calculating the used percentage of MVV, one divides VE at  $\text{VO}_{2\text{peak}}$  with MVV. Thereafter, BR can be calculated by subtracting 100 from the used percentage of MVV. BR represents the remaining respiratory capacity, often presented in percentage of the MVV(10).

### **3.1.4 Measurement of EFL**

With a spirometer turbine which is attached to the CPET while running, measurement of flow limitation can be done. EFL is defined by Johnson as the tidal exercise volume loop (extFVL) that meets or exceeds the maximal flow volume loop (MFVL) (20). While the term extFVL is used for the tidal exercise flow-volume loop, meaning the exercise tidal volume loop of the volume that is produced during exercise, the MFVL represents FVC(20).

## 3.2 Ventilation during exercise in without having asthma

Usually, BF should increase during exercise. It is mostly the VT that increases ventilation during the low level of exercise. When exercise demand progresses, both the VT and BF increase until 70-80% of  $\text{VO}_{2\text{peak}}$  is achieved, thereafter the BF continues to rise (10,20). VT usually reaches its plateau level at 50-60% of the VC. BF increases in both untrained adolescents and athletes (20).

When VE increases exponentially to the increase in  $\text{VO}_2$  in CPET-testing, is when the ventilatory threshold is met (10). The increase of lactate will stimulate the production of  $\text{CO}_2$ , in terms of VE (10). A higher ratio than  $>34$  of  $\text{VE}/\text{VCO}_2$  at the ventilatory threshold can indicate poor ventilatory efficiency, while  $<30$  at the ventilatory threshold is normal (14). The ratio of  $\text{VE}/\text{VCO}_2 < 36$  at  $\text{VO}_{2\text{peak}}$  is considered normal, while values  $<36$  are considered pathological according to ATS (10).

Normally, EILV increases in individuals without asthma when exercise demand progress, as the exercise intensity and VE increases. As the exercise intensity and VE increases, the EELV continues to fall (20).

At peak exercise intensity, one  $\text{VO}_{2\text{peak}}$ . When  $\text{VO}_{2\text{peak}}$  is achieved, one would expect that people without asthma with normal cardiorespiratory fitness usually have around 20-40 % BR (15). A 20-40% BR could indicate no ventilatory restriction to exercise. However, it is not uncommon that trained people without asthma have a low BR if they use nearly all of their VC (15)

## 3.3 Ventilation during exercise while having asthma

The VC is reduced in people with EFL (20). Due to the early onset of EFL, EELV may increase with even light activity. An increase in EELV can indicate hyperinflation (20). However, we do not yet understand fully the mechanism by which EELV rises (20). The increase of EELV increases the work and oxygen cost of breathing and decreases the endurance of the inspiratory muscle, and could increase the BF. As BF increases during exercise due to higher ventilatory demands, this can cause a further increase in the EFL (14, 20).

The increase in EELV that occurs with EFL decreases optimal inspiratory muscle length and increases the work and oxygen cost of breathing (20, 21). Furthermore, the increased EELV and the following constraint of  $V_T$  increase could possibly contribute to EFL in people with lung disease (20). Figure 1 below shows possible changes of EELV, EILV, and EFL from rest to exercise.




Figure 1. Ventilatory changes from rest (A) to exercise (B). Taken with permission from *Exercise and Sport Sciences Reviews*, Volume 41 Issue 1. Tony Babb. Exercise Ventilatory Limitation: The Role of Expiratory Flow Limitation. p. 14. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529766>

At  $VO_{2peak}$ , the percentage of BR could be low (<15 %) and indicated that people have a ventilatory limitation to exercise (15). However, it is possible that also that trained people with asthma have a low BR if they use nearly all of their VC (15).

The ventilatory efficiency is reduced by an increased VE in people with mild to moderate EFL. MVV and VE are described together as the dyspnea index ( $VE/MVV$ ), a ratio given for a particular workload, whereas an increased ratio of dyspnea index could affect exercise tolerance. Dyspnea index can reflect limitation during exercise when MVV is low and when VE is high (22). Several studies have demonstrated an association between dyspnea intensity during exercise and that dyspnea can be an indication of lung hyperinflation (20).

### **3.4 Previous research on exercise and bronchial hyperresponsiveness**

Schichlone, Morici and Zangla reports that exercise can have a beneficial role in asthma treatment and asthma management, for reducing the BHR in adults with asthma (23). Ram, Robinson, and Black support this as well (24). BHR was decreased after the exercise intervention for mild untreated adults with asthma in the study of Hallstrand, Bates, and Schoene (22). Wanrooj, Willeboordse, Dompeling et al. also concluded that exercise has positive effects on cardiorespiratory fitness in children and adolescents and that exercise reduces BHR. The reason for this, is the lower VE among children with better cardiorespiratory fitness, will have for a given workload (8). Decreased BF after the exercise intervention in adults was also seen in the study of Hallstrand, Bates, and Schoene (22). Hallstrand, Bates, and Schoene demonstrated a decrease of hyperpnea in exercise in adults due to increased ventilatory efficiency (22) Increased BF could probably stimulate the EIB, so a lower VE is, therefore, beneficial (8,22). Exercise for individuals with asthma is considered safe (8,10).

## **4.0 Extended discussion:**

### **4.1 Statistical considerations**

Baseline characteristics in table 1 and the main results in table 2 in the article are given as median values with interquartile range (IQR) due to skewed data. When using IQR, one uses the range between the 25% lowest and 25 % highest values middles score rather than the extreme scores (25). IQR is, therefore, less affected by extreme scores than if one uses minimum and maximum values for dispersion measure. Hence, IQR as useful for skewed data (25). Use of the median for describing the central tendency of the data is also more robust since extreme values can influence the mean value more (26). Non-parametric tests were used for analyzing differences between pre and post measurements, due to the skewed distribution of data. In addition, a low sample size as in our study ( $n=15$ ) often requires non-



parametric testing since extreme values will make a bigger impact on a small group. It is usual to use a non-parametric test when the sample size is below 30 (26). Non-parametric statistical tests are more robust than parametric tests since these are less affected by extreme values. Correlation values in table 3 in the article are given with Spearman's rho ( $\rho$ ). Munro's descriptive terms for the strength of correlation coefficients have been used to interpret the strength of the relationship between variables (26). Categorical variables (gender) are presented as frequencies and percentages.

The statistical methods used to test change from pre to post measurements were the Wilcoxon Signed Rank Test, which one uses for dependent continuous variables, for comparing two related samples (26). Wilcoxon Signed Rank Test is a non-parametric alternative to the paired t-test (26). BR and EFL were all measured at  $VO_{2peak}$  are all dependent since we are investigating whether these variables change due to the exercise intervention. Of the same reason, MVV, FEV<sub>1</sub>, FVC, VE, dyspnea index, VE/ $VO_2$  VE/ $VCO_2$  and  $VO_{2 peak}$  is also considered as dependent variables. P-values  $<0.05$  was considered as statistically significant. That means that we can accept a margin of error of 5%, a 5 % probability that our statistical conclusion is wrong. Occasionally a more stringent level of 0.01 is used, for example when the consequences for making wrong clinical decisions cause severe effects on health (26), which is not the case in this present study.

All tests were two-tailed, for the possibility of testing the relationship between variables in both directions (26). These variables were  $VE_{peak}$  and EFL, EFL and  $VO_{2 peak}$  and BR. All correlation variables that were checked, were at  $VO_{2peak}$  at the post-test, after the exercise intervention.

## **4.2 Reliability and validity of the measurement of extFVL/MFVL-analysis during exercise**

Few studies exist concerning the reliability and validity of the extFVL/MFVL-analysis. However, there are some things that can affect the reliability of the extFVL/MFVL-analysis such as placement of extFVL within MFVL (20). If the IB maneuvers are not correctly done,

this can give a false presentation of the EFL. If the person is not fully inspiring, this will cause the extFVL to be smaller and shifted more to the left within the MFVL, underestimating the EFL of the adolescents with asthma. Hence, practicing IB maneuvers is critical for the reliability of the EFL/MFVL-analysis (20). According to Johnson, for most patients, it is likely that adequate IB maneuvers can be performed during exercise if enough time is spent prior to exercise practicing IB-manuevers (20). Another critical issue regarding reliability is whether the computer understands when the IB maneuvers are done. Therefore, IB maneuver was manually checked in addition.

### **4.3 Reliability and validity of methods of calculating BR**

Since  $FEV_1$  correlates with MVV (17), one can use  $FEV_1 \times 35$  to estimate MVV, but Hallstrand suggests that subtle changes in lung function or airway reactivity not always can be detected by the  $FEV_1$  maneuver (17,22). However, using directly measured MVV has shortcomings for assessing ventilatory limitation (20). First, there are significant differences in breathing pattern for the MVV and the hyperpnea which is reflex-driven in the exercise, since it not represent the typical breathing pattern during exercise (20). Klas and Dempsey demonstrated in 1989 the work of breathing (WOB) was higher in MVV than the hyperpnea during exercise (27), as shown in figure 2 below. When maximal flow rates were achieved for brief periods via the MVV maneuver, the EELV was high, and therefore the ventilatory work greatly exceeded that achieved in peak exercise intensity (27). Since one cannot do MVV over 15 seconds, this confirms the excessive work and cost which is not needed in exercise. Second, the MVV only measures the maximal capacity for the lungs and does not give any specific information about what type of ventilatory constraint there is, such as inspiratory flow, high inspiratory elastic load or EFL (20). Third, the MVV is also motivationally dependent, and whether there is a consistent relationship between the exercise ventilation and MVV to influence the perception of dyspnea of exercise tolerance, is yet to be further examined (20).




Figure 2: The difference in breathing pattern and EELV when the MVV maneuver is performed (left) relative to the same persons at peak exercise intensity (right). Reprinted from CHEST. Bruce D. Johnson, Idelle M.

Weisman, Jorge R Zeballos, Ken C Beck. Emerging Concepts in the Evaluation of Ventilatory limitation During Exercise: the exercise tidal flow volume-loop. Volume 116, Issue 2 p. 493 Copyright (1999) with permission from Elsevier.

## 4.4 Strength and limitations of the study

80% of all included participants at baseline completed the entire intervention, which counts a strength. Another strength with the study, is the use of extFVL/MVFL-analysis when assessing EFL at  $VO_{2peak}$ , where one can extract more information from the flow curves, such as; 1) the degree of EFL, since EFL is not an “all or nothing” phenomenon, 2) the curves shows us breathing strategy, such as changes in the EELV 3) elastic load, represented by EILV (EILV/TLC or the VT relative to the IC (20). ExtFVL/MFVL-analysis gives basically a good visualization of how much of the amount of VC which is utilized and how great BR which potentially can be increased (20). Plotting the extFVL with the MFVL gives a quantification of the sources of mechanical constraint and it not as motivationally dependent as the MVV maneuver, which adds more information during CPET, such as BF and VT (20).

However, the use of extFVL/MFVL-analysis can also be seen as a limitation, because extFVL/MFVL-analysis is not an established method and there exist no studies to compare with (20). Hence, results which are considered normal is yet unclear. The extFVL/MFVL-analysis is also subjective because considering the extent of EFL is dependent on the accuracy of the person evaluating the results from the extFVL/MFVL-analysis (20). Plotting of extFVL within MFVL is also done manually and therefore, non-accuracy with measurement can influence the reliability of the measurement. A limitation with extFVL/MFVL-analysis is the quality of the IB maneuvers, and whether the recordings represent the full IC of the person (20). Plotting extFVL/MFVL-analysis makes testing and analysis more complex due to the management of several variables at once. Also, technical accuracy is dependent on the assessment of extFVL/MFVL-analysis (20). Estimating the MVV for calculation of BR through multiplying  $FEV_1$  with 35 is also seen as a reliable and reproducible method (17).

CPET is a gold standard for evaluating exercise intolerance with lung diseases, according to Palange et al, but should be used together with spirometry for diagnostic purposes (28).

$VO_{2peak}$  was used instead of  $VO_{2max}$ , so participants that did not meet  $VO_{2max}$  criteria did not have to be excluded from the analysis when there from before were few participants in our study. When using the term  $VO_{2peak}$ , there is no need for evidence of plateauing, which one will need to determine when using  $VO_{2max}$  is reached (10). Children often do not manage to achieve a plateau in  $VO_2$  despite signaling that they have reached their limit of tolerance. Hence, using  $VO_{2peak}$  as a term will be more suitable (29).

Using BMI z-score instead of BMI-cut offs can be considered as a strength since they are more suitable for adolescents. The widely used BMI cut off for overweight, obesity, and thinness, are based on and linked to adults BMI-cut offs (30).

The main limitation was the small study sample size since the sample size cannot be used in an effect-study (26). Representativeness is harder to achieve with low sample size (26). Since most of the adolescents in this study had well-controlled asthma, the findings of the main study are less representative for other adolescents with less-controlled, moderate or severe asthma. EFL and BR could have been worse in groups with less-controlled asthma and moderate or severe asthma.

Due to the single group design and low sample size, there is no chance for random allocation of participants into several groups, nor is there an opportunity for a comparison of EFL and

BR between adolescents with asthma and adolescents without asthma (26). Often, this type of design with no comparison or random allocation of participants between several groups is considered a “weak” research design (26). When the sample size is small, this can higher the probability of type two error, meaning no detection of changes when there, in reality, are changes (26). However, low sample size and design can be appropriate for this type of study. Few studies assess changes in EFL and BR in adolescents with asthma. When few studies exist, doing research with a low sample size first before conducting random controlled trials (RCT) is preferable so that unnecessary recourses in terms of time, subjects and financial cost can be avoided in a RCT. We tried to recruit several participants in this study, but recruiting was difficult. Several potential participants were occupied with school and other activities to and declined to participate.

Some participants had to stop before reaching full exhaustion at the post-test. This can be a limitation for the study since this can influence the results in terms of no improvement of  $VO_{2peak}$ , which is strange after an exercise intervention. However, the reasons for early termination of CPET was to avoid injuries due to stumbling. Safety of the participants during testing should always be prioritized. Another reason for early termination CPET was that participants were not motivated to run to full exhaustion due to pain in legs while running. As test leaders, we could only encourage, not force, adolescents, to run until full exhaustion.

## **4.5 Ethical considerations**

PLAY has been approved of the Regional ethics committee (REK no: 2017/1320). Name of the participating adolescents and identification code looked down separately. Data were de-identified before plotted into SPSS. To ensure informed consent, potential participants and their parents got a written letter about participation when they were recruited (appendix 2a and 2b). In this letter, adolescents got information about the background and aims of the study, what the participation would mean for them, and the potential benefits and costs with joining the study. Adolescents were also informed that participation was voluntary and that they could decline from the project without consequence for treatment. It was mentioned that the results will be treated anonymously, and they had the right to get information about the results of projects. For all participants, we received a signed consent form from participants and their parents (appendix 2a-b). Participants over 16 years old were first contacted before

parents, as they possess the right to give consent according to Norwegian law (31) For participants under 16 years old, the parents were contacted first.

Based on previous experiences and research concerning the exercise and the intensity level that was tested, adolescents did not have any risk of injury, pain or mental strain (8,10). However, children and adolescents may be considered as vulnerable research participants need for extra protection and support (32). Before each session adolescents were instructed to use asthma medication, as prescribed by their doctor. For safety reason, nebulizer and extra asthma medication were available. Instructors were supervised in use of these. The exercise was done with two instructors making sure the training was safe, and during the opening hours of the training facilities if case extra assistance was needed. The instructors were supervised on how to give extra rescue medicine and there was always extra medication available if needed, such as a nebulizer, an aero chamber and Ventolin. Participation in the study was of no greater risk than in daily life for adolescents with asthma. The CPET is a safe type of test, where the risk of death for patients between 2 and 5 per 100 000 exercises done(10). Testing and exercise in the intervention were done with safety supervision and after strict safety procedures, and therefore a small risk of harm for participants. Only research members who were lab certified, who knew about the risk of testing, when to not test and knew when to terminate during CPET, supervised the testing (10). Also, a medical responsible doctor was available at testing. Accuracy was emphasized through following lab procedures and calibration, ensuring as much accuracy of testing as possible.

Adolescents had to use time on this project and travel back and forth from training and testing facilities. However, there were benefits of participating in this study, such as the possibility of improving cardiorespiratory fitness, chances to make friends with the other participants and being in part of a group, especially with others with the same disease. Knowledge from the present study could also be of benefit for other adolescents with asthma and for knowing better how to plan an RCT later.

The main study got financial support from the Norwegian Association of Asthma and Allergy (NAAF) to pay the instructors, but master students did not receive any funding.

Being open about the results no matter if they are significant or not is important ethically. Not presenting them as improvement or changes when the p-values were above the chosen significance level, have been an important decision. This is because we cannot know whether

the results occurred by chance or because of the intervention. Changes in “wrong” directions or no changes at all can be as important findings as changes in “right” directions.

There was taking considerations to protect revealing the identity of adolescents with asthma participating in the study. The expression “from two study sites in Southern Norway” in the article was a conscious choice, making it harder to guess who the participating adolescents with asthma were. Individual changes, as shown in figure 1 and 2 in the article are presented without ID, to ensure confidentiality for adolescents with asthma participating in the study.

## **4.6 Future research**

Additional work to better understand the ventilatory mechanism in adolescents is needed. The effect of exercise at  $VO_{2peak}$  has on BR and EFL should be investigated in randomized controlled trials. The changes of BR and EFL at  $VO_{2peak}$  should be considered along with dyspnea index,  $VE/VCO_2$ , EELV, EILV, and  $VE_{peak}$  to better understand how BR and EFL at  $VO_{2peak}$  change due to an exercise intervention. Also, changes at submaximal exertion could be of interest as well as with  $VO_{2peak}$ , since exercise is often done at submaximal exertion. Assessing EFL through comparing the extFVL within MVFL should be used, for better visualization of a potential EFL during exercise and the extent of EFL (20). However, the extFVL/MFVL-analysis should be further examined for reliability and validity (20).

## 5.0 References

1. Papadopolous NG, Arakawa H, Carlsen KH, et al. International Consensus on (ICON) pediatric asthma. *Allergy* 2012;67(8): 976-997 doi: 10.1111/j.1398-9995.2012.02865.x.
2. The Norwegian Public Health Institute (NIPH). Asthma and Allergy in Norway. [Public Health Rapport] 2016. Accessed from <https://www.fhi.no/en/op/hin/health-disease/asthma-and-allergy-in-norway---publ/> 12<sup>th</sup> of May 2019
3. Hovland, V., Riiser, A., Mowinckel, P et al. Asthma with allergic comorbidities in adolescence is associated with bronchial responsiveness and airways inflammation. *Pediatr Allergy Immunol* 2014;25(4), 351-359.
4. Lødrup Carlsen KC, Håland G, Devulapalli CS et al. Asthma in every fifth child in Oslo, Norway: a 10-year follow up of a birth cohort study. *Allergy* 2006;61(4), 454-460 doi: 10.1111/j.1398-9995.2005.00938.x
5. Chung HL. Asthma in childhood: a complex, heterogeneous disease. *Korean J Pediatr* 2011;54(1):1–5. doi:10.3345/kjp.2011.54.1.1
6. Eichenberger PA, Diener SN, Kofmel R et al. Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis. *Sports Med* 2013; 43: 1157-70. Doi: 10.1007/s40279-013-0077-2.
7. Del Giacco SR, Firinu D, Bjermer L et al. Exercise and asthma: an overview. *Eur Clin Respir J* 2015;2:27984 doi: 10.3402/ecrj.v2.27984
8. Wanrooij VH, Willeboordse M, Dompeling E et al. Exercise training in children with asthma: a systematic review. *Br J Sports Med* 2014; 48(13):1024-31 doi: 10.1136/bmjsem-2018-000409
9. Carlsen K, Engh G, and Mørk M. Exercise-induced bronchoconstriction depend on exercise load. *Respiratory Medicine* 2000;94(8):750-755 doi: 10.1053/rmed.2000.0809



10. American Thoracic Society/American College of Chest Physicians. ATS/ACCP statement on Cardiopulmonary Exercise Testing. *Am J Crit Care Med* 2003;167(2): 211-277 doi: 10.1164/ajrccm.167.10.950
11. De Aguiar K, Anzolin M and Zhang L. Global prevalence of exercise-induced bronchoconstriction in childhood: A meta-analysis. *Pediatr Pulmonol.* 2018;53(4):412-425 doi: 10.1002/ppul.23951
12. William B, Hoskins G, Pow J et al. Low exercise among children with asthma: a culture of protection? A qualitative study of experiences and beliefs. *Br J Gen Pract* 2010; 60(557): 319-326 doi: 10.3399/bjgp10X515070
13. Carson KV, Chandratilleke MG, Picot J, Brinn MP et al. Physical training for asthma. *Cochrane Database Syst Rev* 2013(9): CD001116. doi: 10.1002/14651858.CD001116.pub4.
14. Babb TG. Exercise Ventilatory Limitation: The Role of Expiratory Flow Limitation. *Exerc Sports Sci Rev.* 2013; 41(1):11-8 doi: 10.1097/JES.0b013e318267c0d2
15. Larsen, KO. Belastningsundersøkelse for vurdering av kardiopulmonar funksjon. *Hjerteforum.* 2011;24: 17-25
16. Hauge, Anton. Lungeventilasjon. In: Store medisinske leksikon. 2018. Accessed from <https://sml.snl.no/lungeventilasjon> 12<sup>th</sup> of May 2019
17. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J.* 2005;26:319-338 doi: 10.1183/09031936.05.00034805
18. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J.* 2012;40(6):1324-43 doi: 10.1183/09031936.00080312.
19. Barreiro TJ, and Perillo I. An Approach to Interpreting Spirometry Am Fam Physician. 2004;69(5):1107-1115
20. Johnson BD, Weisman IM, Zeballos RJ, and Beck KC. Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. *Chest.* 1999;116(2):488-503 doi: 10.1378/chest.116.2.488

21. Lind F and Hesser CM. Breathing pattern and lung volumes during exercise. *Acta Physiol Scan* 1984;120(1): 123-129 doi: 10.1111/j.1748-1716.1984.tb07381.x
22. Hallstrand, TS Bates, PW and Schoene RB. Aerobic Conditioning in Mild Asthma Decreases the Hypernea of Exercise and Improves Exercise and Ventilatory Capacity. *Chest*. 2000;118(5): 1460-1469 doi: 10.1378/chest.118.5.1460
23. Schicilone N, Morici G, Zangla D, et al. Effects of exercise training on airway closure in asthmatics. *J Appl Physiol* 2012; 113(5): 714- 718 doi: 10.1152/jappphysiol.00529.2012.
24. Ram FS Robinson, SM and Black PN. Effects of physical training in asthma: a systematic review. *Br J Sports Med* 2000;34(3):162-167 doi:10.1136/bjism.34.3.162
25. Vincent, WJ. Statistics in Kinesiology. Third edition. Champaign, IL. Human Kinetics Publishers; 2005
26. Carter R, and Lubinsky J. Rehabilitation research. Fifth edition. Principle and Application. St. Louis, Miss: Elsevier Saunders; 2016
27. Klas J, and Dempsey J. Voluntary Versus Reflex Regulation of Maximal Exercise Flow: Volume Loops. *American Review of Respiratory Disease*, 1989;139(1)150-156 doi: 10.1164/ajrccm/139.1.150
28. Palange P, Ward SA, Carlsen, K-H et al. *Eur Respir J* 2007;29:185-209 doi:10.1183/09031936.00046906
29. Barker AR, Williams CA, Jones AM et al. Establishing maximal oxygen uptake in young people during a ramp cycle test to exhaustion. *Br J Sports Med*. 2011;45 (6):498–503 doi: 10.1136/bjism.2009.063180
30. Cole T, Flegal K, Nicholls D et al. Body mass index cut offs to define thinness in children and adolescents: international survey. *BMJ*. 2007;335(7612):194 doi: 10.1136/bmj.39238.399444.55
31. Helseforskningsloven. Lov om medisinsk og helsefaglig forskning. 2008. m.v av 2008. - 06-20, number 44 [Health Research Law. The law about medical and healthcare professional research].

32. Solbakk JH. Sårbare grupper. Accessed from  
<https://www.etikkom.no/FBIB/Temaer/Forskning-pa-bestemte-grupper/Sarbare-grupper/> 13<sup>th</sup>  
of May.

## **Part 2: Changes in breathing reserve and expiratory flow limitation at peak exercise intensity after a 10-week exercise intervention in adolescents with asthma**

1. Anette Nielsen

Faculty of Medicine, University of Oslo, Oslo, Norway

<https://orcid.org/0000-0002-3371-8276>

2. Thomas Westergren

Faculty of Health and Sport Sciences, University Of Agder, Kristiansand Norway

3. Julie Stang

Department of Sport Sciences, Norwegian School of Sport Science, Oslo, Norway

3. Trine Stensrud

Department of Sport Sciences, Norwegian School of Sport Science, Oslo, Norway

Wordcount: 3240

Tables: 3

Figures: 2

### **Correspondence to:**

Anette Nielsen

Institutt for helse og samfunn, Faculty of Medicine

University of Oslo

Postbox 1089 Blindern, 0317 Oslo, Norway

+47 480 033 629

[anette.nielsen@studmed.uio.no](mailto:anette.nielsen@studmed.uio.no)

## ABSTRACT

**Introduction** The aim of this study was to assess changes in breathing reserve (BR) and expiratory flow limitation (EFL) at peak oxygen uptake ( $VO_{2peak}$ ) after an exercise intervention in adolescents with asthma.

**Methods** Fifteen adolescents with asthma, aged 13-18 years, participated in one-hour of exercise two times a week for ten weeks. Data collection included pre- and post-testing with spirometry at rest and EFL and BR at  $VO_{2peak}$  were examined when adolescents performed cardiopulmonary exercise tests (CPET) with intrabreath (IB)-maneuvers. Wilcoxon Signed Rank Test was used to determine the significance of the change in variables before and after the intervention, while Spearman's rho was used to assess correlation at post-assessment. Values are measured at  $VO_{2peak}$  and are presented as median with interquartile range unless otherwise stated.

**Results** Compared to baseline, EFL remained unchanged from (0.0 [23]) to (0.0 [0.0]). BR was before the exercise intervention (-0.6 % [15.6]) and (0.5 % [13.2]) after the exercise intervention.  $VO_{2peak}$  was before the exercise intervention (39 ml/kg/min [16.2]) and (42.6 ml/kg/min [19.5]) at post-assessment. There was a negative correlation of  $\rho = -0.4$  between BR and  $VO_{2peak}$ .  $VO_{2peak}$  showed also a negative correlation of  $\rho = -0.4$  with EFL. Minute volume (VE) showed a correlation of  $\rho = 0.1$  with EFL while BR and  $VE_{peak}$  had a correlation of  $\rho = 0.3$ ). All correlation variables checked were at post-assessment and non-significant.

**Conclusion** BR remains low and there is no change or findings of EFL after a 10-week exercise intervention, in adolescents with asthma at  $VO_{2peak}$ , compared with the baseline assessment

### Key messages

- This study aims to describe changes in ventilatory limitation among adolescents with asthma participating in an exercise intervention.
- Breathing reserve was low both before and after the exercise intervention for adolescents with asthma. No expiratory flow limitation was found before or after the exercise intervention for adolescents with asthma.

**Abbreviations:** EFL: Expiratory flow limitation BHR: Bronchial hyperresponsiveness

**EIB:** Exercise-induced bronchoconstriction **BR:** Breathing reserve **PA:** Physical Activity  
**HR<sub>max</sub>:** Maximum heart frequency **CPET:** Cardiopulmonary exercise test **VE:** Minute ventilation **MVV:** Maximal voluntary ventilation **EELV:** end-expiratory lung volume **FEV<sub>1</sub>:** forced expiratory volume in 1 second **BF:** breathing frequency **VC:** vital capacity **VE:** minute ventilation: **VO<sub>2</sub>:** oxygen uptake **VO<sub>2-peak</sub>:** Highest VO<sub>2</sub> achieved on a test performed to limit of tolerance **VT:** tidal volume **EILV:** End inspiratory lung volume, **extFVL:** tidal exercise flow-volume loop **MFVL:** maximal flow-volume loop **IC:** inspiratory capacity **ATS:** American Thoracic Society **ICON:** International consensus on pediatric asthma **PA:** Physical Activity

## INTRODUCTION

According to the international consensus on pediatric asthma (ICON), asthma can be defined as

[...]A chronic inflammatory disorder associated with variable airflow obstruction and bronchial hyperresponsiveness (BHR). It presents with recurrent episodes of wheeze, cough, shortness of breath and chest tightness. <sup>1</sup>

The worldwide burden of asthma continues to rise.<sup>2</sup> Asthma is considered one of the most common chronic diseases in children.<sup>1</sup> Bronchial obstruction triggered by intensive physical activity (PA), exercise-induced bronchoconstriction (EIB), is not unusual for adolescents with asthma.<sup>3</sup> Asthma can limit the participation of PA for adolescents, for avoiding EIB and dyspnea in exercise.<sup>4</sup> Dyspnea is regarded as the subjective perception of breathless, but whether this represents expiratory flow limitation (EFL) remains unexplained to this date.<sup>5</sup> EFL is defined as the percent of tidal expiratory flow (extFVL) that meets or exceed the maximal flow volume loop (MFVL).<sup>6</sup> This means, how much of the ventilatory output that closely approaches or meets the ventilatory capacity (VC).<sup>5</sup> There are a few studies that examined EFL in children without asthma.<sup>7,8</sup> In children without asthma, one will expect that children will have EFL during exercise, due to different regulation in children than in adults.<sup>7</sup> In the study by Nourry et al. 2006, EFL was examined in eighteen pre pubescent children without asthma during maximal exercise, whereas ten of the eighteen children had EFL at maximal exercise.<sup>7</sup> However, in adolescents with asthma, few studies have examined EFL at VO<sub>2peak</sub>.

Reduced breathing reserve (BR), <15%, at peak oxygen uptake ( $\text{VO}_{2\text{peak}}$ ), can also indicate a ventilatory limitation in adolescents.<sup>9,10</sup> BR is the difference between measured maximal voluntary ventilation (MVV) and the ventilation (VE) measured at  $\text{VO}_{2\text{peak}}$ .<sup>6</sup> At  $\text{VO}_{2\text{peak}}$ , one would expect that adolescents without asthma, have around 20-40% BR.<sup>9</sup> However, it is not uncommon for adolescents with increased  $\text{VO}_{2\text{peak}}$  to have a low BR if they use all of their ventilatory capacity (VC).<sup>9,10</sup> To our knowledge, it is not known whether BR in adolescents with asthma can be changed after an exercise intervention.

The aim of this article is to describe how BR and EFL at  $\text{VO}_{2\text{peak}}$  change after a 10-week exercise intervention, compared with baseline assessment before the intervention.

## **METHODS**

### **Design**

The present study was a subproject of Physical Activity and Asthma in Youth (PLAY) study, an exercise intervention study with a pre-post single group design. The comparisons are made within this group and no control group was included, making this study a within-group design.<sup>ref</sup>

### **Exercise intervention**

The study was conducted at two study sites in southern Norway at winter/spring and autumn/winter months apart from pollen season. The intervention period was over ten weeks, two times a week, one hour each time and located indoors. The activities were taken from an activity bank developed by bachelor students in sport from the University of Agder and were adjusted with what motivated the participants. The exercise was a combination of group-based activities indoors and outdoors based on relays, obstacle courses, and circuit training, and activities were adjusted so they were easy to complete in relation to gross motor and coordination skills. The exercise intervention was lead by two experienced sports instructors from two study sites. One of the two was present to organize activities, while the other participated in the session along with the adolescents.

The adolescents wore a heart rate (HR) monitor (Polar M400, Polar Electro OY, Kempele, Finland) during all sessions for the recording of exercise intensity. The HR data from each

session was registered and transferred to a computer at the lab and was exported into excel, and then calculated.

To be included in the study, participants had to be between 13 and 18 years of age. Symptoms of dyspnea, tightness in the chest and/or wheezing in the chest had to be experienced during the last 12 months, or use of asthma medications during the last months. A pulmonologist, allergist or pediatrician had to confirm the asthma diagnosis. In addition, participants had to be living within a one-hour traveling distance from the training facilities. Exclusion criteria included comorbidities such as upper airway infection the last week before pre-test, movement problems, heart disease, cancer and diabetes type 1 and/or travel distance above one hour from training facilities. Participants were recruited through the list of the allergist, which could confirm that their participation was medically safe and that participants met the inclusion criteria. Participants and their parents were informed about the potential burden with participation.

### **Measurement of height, weight, and body mass index**

Height and weight were measured by a stadiometer (Seca 713, Birmingham, UK) to the nearest 0,5 cm and 0,1 kg in daily clothes without shoes. Body mass index (BMI) was calculated as body mass (kg) divided by height (m)squared and defined with standard deviation scores (z-scores) with international limits for BMI adjusted for age and sex according to Cole et al.<sup>11</sup>

### **Measurement of intensity during the intervention**

For the recording of exercise intensity during the exercise intervention, participants wore a heart rate (HR) monitor (Polar M400, Polar Electro OY, Kempele, Finland). The HR data from each session was registered and transferred to a computer at the lab and was exported into excel, for further calculation of HR data.

### **Measurement of lung volumes and flow limitation**

Before CPET, gas calibration was done. When calibrating gas analyzer, known gas concentrations that spanned the range of expected measurements were used. The chosen exercise protocol for CPET was a modification of Balke.<sup>12</sup> For CPET, the mask was adjusted



and placed on the participant's nose and mouth and connected to an oxygen analyzer ((OxyconPro, Jaeger, Würzburg, Tyskland). Breath by breath method was used. This method analyzes the volume and gas of every expiratory breath.<sup>10</sup> Participants ran on a treadmill (Woodway, ELG 90/200 Sport, Weil Am Rhein, Germany) with increasing speed and incline every second minute after a warm-up of 4 percents inclines and 4,0 km/h during the first three minutes. Participants were encouraged to run to exhaustion.  $\text{VO}_2$  was measured at peak exercise intensity at CPET to determine  $\text{VO}_{2\text{peak}}$ . VE, EELV, EILV, and VE/ $\text{VCO}_2$  ratio was measured at  $\text{VO}_{2\text{peak}}$  during CPET. Intrabreath measurements were used for assessment of expiratory flow limitation (EFL) during exercise. During the CPET extFVL was recorded using intrabreath (IB) maneuver so that extFVL could be placed within the MFVL obtained from the spirometry performed at rest before the CPET.<sup>6</sup> If possible, the second last extFVL recorded before the IB maneuver was used for analysis. If not possible to use the second last extFVL due to low quality, such as irregular loop or no recording, the last loop before the IB maneuver was used. The second loop after a full IB maneuver was used a third choice as long as there were no signs of drifts before and after the IB maneuver or within the first extFVL recordings.<sup>6</sup> If there was not possible to obtain a tidal loop without drift, recordings were set to missing, and therefore no measure of EELV, EILV or EFL could not be given for that specific time point. Researchers conducted manual control of each IB recording. Only recordings with a rapid inspiration followed by a comparable expiration and a similar extFVL as before the maneuver were accepted. The percentage of the extFVL that meets or exceeds the MFVL, indicated the presence and degree of EFL.<sup>6</sup> Data were analyzed with the software program SentrySuite 2.21, CareFusion, Hoechst, Germany. The CPET was only done by research members with lab competence and certification. The extent of EFL was defined where extFVL meets or exceeded the MFVL from rest according to Johnson.<sup>6</sup>

### **Measurement of lung function**

Before spirometry, a 3-liter calibration syringe was used to calibrate the flow sensor. During spirometry testing, the adolescents were seated on a chair and given a nose clip. Lung function was assessed with MasterScreen Pneumo spirometer (CareFusion, Würzburg, Germany). For each adolescent, three measurements of FVC and  $\text{FEV}_1$ . The best FVC and  $\text{FEV}_1$  measurements were kept for determining the greatest MFVL loop along with the extFVL.<sup>6</sup> Ethnicity, gender, height, weight, and age were plotted into the computer along for adjusting the spirometric values according to the recommendation of the American Thoracic

Society (ATS).<sup>10</sup> The expected spirometry values were registered as a percentage with reference values according to Quanjer et al.<sup>14</sup>

### **Measurement of maximal voluntary ventilation and breathing reserve**

For calculating BR, MVV was estimated by multiplying FEV<sub>1</sub> with 35, as this method correlates with MVV.<sup>ref</sup> FEV<sub>1</sub> was measured in a Master Screen spirometer (CareFusion, Würzburg, Germany), and thereafter multiplied with 35. VE at VO<sub>2peak</sub> during CPET was then divided by the estimated MVV through FEV<sub>1</sub> x 35<sup>13,15</sup>. This gave the used percentage of BR. For calculating the remaining BR to, this value was then subtracted by 100.

### **Measuring asthma control**

Asthma control questionnaire (ACQ) was used to determine how well-controlled asthma the adolescents had.<sup>16</sup> ACQ was measured at baseline and after the intervention. Participants answered the questionnaire on question 1 to 6. The last question, 7, was filled out by test leader based on FEV<sub>1</sub> before CPET. A score <1.0 will have adequately controlled asthma.<sup>16</sup> Scores >1.0 will be viewed as not well-controlled asthma.<sup>16</sup>

### **Calculation of dyspnea index**

Dyspnea index at VO<sub>2peak</sub> was calculated by dividing VE at VO<sub>2peak</sub> with the estimated MVV, using FEV<sub>1</sub> multiplied 35.<sup>17</sup>

### **Statistical analysis**

Statistic analysis was run by the Statistical Program for Social Services (SPSS), version 25, (SPSS Inc., Chicago, USA). SPSS for Windows was used. P-values <0.05 was considered statistically significant. Due to skewed data and low sample size non-parametric test was done. Variables before and after the exercise program were compared using the Wilcoxon signed rank test. Correlation of the characteristics was checked with Spearman's rho (p).

## **RESULTS**

### **Baseline findings**

Table 1 compares the subject characteristic at baseline in the adolescents who completed and in the adolescents who dropped out of the study. In total, six adolescents with asthma from

two study sites in southern Norway dropped out of the study, three adolescents with asthma from each of the two study sites. The main reason for drop-out was long travel distance, injury and/or that they were occupied with school. Two adolescents with asthma dropped out before the intervention started, while the four dropped during the intervention. As seen in table 1, adolescents with asthma who dropped out were slightly younger than the participants who completed the intervention. In addition, the BMI z-score was higher for the group of adolescents with asthma who dropped out (1.5 [1.3]) than the group of adolescents with asthma which completed 0.5 (1.1). Predicted values of FEV<sub>1</sub> (%) were lower 90.2 (13) in adolescents who completed than those who dropped out (100.5 [23.5]). The ACQ score at baseline was 0.9 (0.9) for the adolescents who completed and 0.9 (0.7) for the adolescents who dropped out, meaning adequate asthma control in both groups.<sup>16</sup> Adolescents who completed the study had lower VO<sub>2peak</sub> (39.0 ml/kg/min (16.2) at baseline than the adolescents who dropped out 45.9 ml/kg/min (14.6). Among those who completed, there were more male (*n*=9) than female adolescents (*n*=6) participating in the exercise intervention.

**Table 1** Subject characteristics at baseline in adolescents asthma (*n*=15) who completed and adolescents with asthma who dropped out of the study (*n*=6). Numbers are given as median with interquartile range (IQR) unless otherwise stated.

| Variables                                | Adolescents who completed the intervention ( <i>n</i> =15) | Adolescents who dropped out of the intervention ( <i>n</i> =6) |
|--|--|--|
| <i>Male, n (%)</i>                       | 9 (60%)  | 3 (50%)  |
| <i>Age (yrs)</i>                         | 16.3 (1.4)   | 15.2(2.1)  |
| <i>Height (cm)</i>                       | 173.5 (10.0)   | 172 (16.8)   |
| <i>Weight (kg)</i>                       | 65.2 (12.5)  | 73.5 (16.4)  |
| <i>BMI z-score</i>                       | 0.5 (1.1)  | 1.5 (1.3)  |
| <i>FEV<sub>1</sub>* (% of predicted)</i> | 90.2 (13)  | 100.5 (23.5)   |
| <i>FVC* (% of predicted)</i>             | 90.6 (16.9)  | 100 (20.3)   |
| <i>FEV<sub>1</sub>/FVC-ratio* (%)</i>    | 90% (10)   | 90%(0)   |
| <i>ACQ</i>                               | 0.9 (0.9)  | 0.9 (0.7)  |
| <i>VO<sub>2peak</sub> (l/kg/min)</i>     | 39 (16.2)  | 45.9 (14.6)  |

---

\*Before asthma medication. *FVC*: Forced vital capacity, *FEV<sub>1</sub>*: Forced vital capacity during the first second, *VO<sub>2peak</sub>*: peak oxygen uptake, *MVV*: Maximum voluntary ventilation, *VE<sub>peak</sub>*: Peak minute ventilation *ACQ*: Asthma control questionnaire *BMI-z-score*: Body Mass Index standard deviation score

### **Attendance rate and heart rate**

The attendance rate during the exercise intervention was 80%. Mean heart rate (HR) during sessions were  $151 \pm 10$  and mean total minutes  $\geq 80\%$  of maximal HR ( $HR_{max}$ ) were  $292 \pm 172$  and  $\geq 90\%$  of  $HR_{max}$  was  $144 \pm 129$ .

### **Change in breathing reserve and expiratory flow limitation**

Mostly, no EFL was seen both before and after the intervention in the group, from 0.0 % (23) to 0.0 % (0.0) Figure 1 illustrates the individual change of EFL in the adolescents at post-assessment. Ten adolescents with asthma had no EFL both before and after the exercise intervention, which can make it hard to notice adolescent with no EFL in figure 1. Four adolescents had a decrease in EFL while one adolescent had an increase in EFL.

Table 2 shows characteristics in adolescents with asthma, comparing before and after the exercise intervention. As figure 2 shows, the adolescent with asthma had different individual changes in BR at  $VO_{2peak}$  at post-assessment. Approximately half of the adolescents increased their BR while the other half of adolescents decreased their BR at post-assessment. Before the exercise intervention, the BR was -0.6% (15.6) while BR was -0.5% (13.2) at post-assessment, as seen in table 2.

Table 3 shows the correlation between the variables. There was a negative correlation between the variables BR and  $VO_{2peak}$  ( $\rho = -0.4$ ), EFL and  $VO_{2peak}$  ( $\rho = -0.4$ ) Also, a positive correlation between VE and  $VO_{2peak}$  ( $\rho = 0.1$ ) and a positive correlation between EFL and BR ( $\rho = 0.3$ ) was seen. All correlation variables were checked at post-assessment and were non-significant.

**Table 2** Cardiorespiratory variables and ventilatory changes of adolescents with asthma, before and after 10 weeks of exercise intervention ( $n=15$ )

| Characteristic          | Before       | After       | p-value |
|-------------------------|--------------|-------------|---------|
| $VO_{2peak}$ (l/kg/min) | 39.0 (16.15) | 42.6 (19.5) | 0.3     |
| $BR$ at $VO_{2peak}$    | -0.6 (15.6)  | 0.5 (13.2)  | 0.6     |
| $EFL$ (%)               | 0.0 (23.0)   | 0.0 (0.0)   | 0.3     |
| $VE_{peak}$ (l/min)     | 111.8(37.0)  | 117.5(61.0) | 0.4     |
| $EELV$ (l/min)          | 1.1 (1.1)    | 1.1 (1.1)   | 0.6     |
| $EILV$ (l/min)          | 3.1 (1.6)    | 3.1 (1.4)   | 0.6     |
| $VE/VCO_2$              | 34.2 (6.2)   | 33.8 (7.6)  | 0.03    |

Data are presented as median. All variables are at peak oxygen uptake ( $VO_{2peak}$ ) Significance was checked with Wilcoxon (IQR).  $BR$ : Breathing reserve,  $VO_{2peak}$ : Peak oxygen uptake,  $VE$ : Minute ventilation  $EELV$ : End-expiratory volume,  $EILV$ : End-inspiratory volume  $VE/VCO_2$ : Ventilatory equivalent of carbon dioxide to the minute volume

### Change in cardiorespiratory fitness

$VO_{2peak}$ , as shown in table 1, were 39.0 ml/kg/min (16.5) at baseline and 42.6 ml/kg/min (19.5) at post-assessment.  $VE/VCO_2$  decreased significantly from 33.4% (5.7) to 33.1% (7.1) ( $p=0.02$ ).  $VE_{peak}$  was 111.8 l/min (37) at baseline and 117 l/min (61) at post-assessment.

**Table 3** Spearman's correlations with significance value between main variables at post-assessment after 10-weeks of exercise intervention in adolescents with asthma

| Correlation variables checked     | Significance ( <i>p</i> ) | Spearman's rho coefficient( $\rho$ ) |
|-----------------------------------|---------------------------|--------------------------------------|
| <i>BR and VO<sub>2peak</sub></i>  | 0.8                       | -0.4                                 |
| <i>EFL and VO<sub>2peak</sub></i> | 0.1                       | -0.4                                 |
| <i>EFL and VE<sub>peak</sub></i>  | 0.4                       | 0.1                                  |
| <i>BR and VE<sub>peak</sub></i>   | 0.3                       | 0.3                                  |

All variables are measured at peak oxygen uptake (*VO<sub>2peak</sub>*) *BR*: Breathing reserve, *EFL*: Expiratory flow limitation, *VE<sub>peak</sub>*: Peak minute volume

## DISCUSSION

Mostly, no EFL before and after the exercise intervention was found in the adolescents (figure 1). However, four adolescents had a reduced EFL at post-assessment, compared with baseline (figure 1). Asthma is a heterogeneous disease,<sup>18</sup> therefore, the exercise intervention could have influenced the adolescents differently. Although no significant change in the group, figure 1 shows a great improvement in these four adolescents. Reduced EFL in these four adolescents could be due to improved medication or improved asthma control along with exercise since several of the adolescents used their medication more often at the end of the intervention. In ten adolescents, there was no EFL at post-assessment which can indicate that exercising at *VO<sub>2peak</sub>* possibly not triggers BHR in adolescents with asthma. Improved asthma control, mild asthma or improved medical treatment of asthma could also be influencing why the adolescents mainly in the group had no EFL. According to Philpott, Houghton and Luke, adolescents are able to participate in any physical activity if symptoms are well-controlled<sup>19</sup> Results could possibly have been different if the adolescents had severe asthma. Reasons for finding no change in EFL could be type two error due to low sample size.<sup>20</sup> Most adolescents had no EFL at baseline, which can make it harder finding a significant decrease of EFL at the post-assessment. Results could possibly have been different if there were some degree of EFL, to begin with.

In the group of adolescents as shown in table 2, approximately no BR was left at post-assessment indicating that the adolescents either still is ventilatory restricted, or that they still use all their VC.<sup>9</sup> Nonetheless, incorrect measurement or estimate of MVV could have been influencing these results. Low sample size and a, therefore, a higher probability for type two error could be reasons for this change.<sup>20</sup> Half of the group of adolescents, had a decrease of BR, as illustrated in figure 2. The decrease of BR in adolescents could also signalize ventilatory limitation or that the adolescents improved their capability of using more of their VC.<sup>9</sup> The rest of the adolescents had an increase of BR, but still under expected values at post-assessment.<sup>9,10</sup> The increase of BR in some adolescents could mean that these adolescents have a larger potential to use of their VC, or that they are not ventilatory restricted to exercise. However, these were still below expected values.<sup>9,10</sup> As one can notice in figure 2, some BR values were below zero at post-assessment. If FEV<sub>1</sub> were not done properly (such as not doing their best effort) or dilation of lungs in exercise can be reasons for the negative values of BR.<sup>21</sup>

As seen in table 3, VO<sub>2peak</sub> had a small negative correlation with BR, which could indicate that with increasing VO<sub>2peak</sub>, BR would possibly decrease. Also, no change of VE<sub>peak</sub> was seen which could have influenced why the adolescents with asthma had no EFL. It is suggested that with a decrease of VE<sub>peak</sub>, this will decrease BHR.<sup>2,17</sup>

There was a small, negative correlation of EFL and VO<sub>2peak</sub>, which possibly could indicate that if VO<sub>2peak</sub> is increased, EFL will decrease. However, the significance of the correlation between EFL and VO<sub>2peak</sub> was low, as seen in table 3. This implies that if we measured the same variables on another group of adolescents with asthma, we would possibly not get the same correlation. When *n* is small it is possible a high correlation coefficient can occur by chance.<sup>22</sup> The correlation between EFL and VO<sub>2peak</sub> does not mean that the change in one of the variables will necessarily produce a corresponding change in the other; for example, when there is no EFL in the adolescents, and EFL is negatively correlated with VO<sub>2peak</sub>.

The dyspnea index did not change, nor was it elevated. According to Hallstrand, Bates and Schoene, the dyspnea index is elevated in adults with EFL.<sup>17</sup> Since the dyspnea index not were elevated in our study, this supports the findings of no EFL in most adolescents with asthma in this study. The significant decrease of the ventilatory equivalent of VCO<sub>2</sub> (VE/VCO<sub>2</sub>) can also indicate improvement of anaerobic threshold, ventilatory efficiency and therefore improved cardiorespiratory fitness.<sup>13</sup> ATS states as well that the ratio of VE/VCO<sub>2</sub> should be

<36 at  $VO_{2peak}$  and a higher value (>36) represents the presence of airway resistance.<sup>13</sup> However, one would expect that with the significant decrease of  $VE/VCO_2$ , significant improvement in  $VO_{2peak}$  at post-assessment was seen along. Significant improvement in  $VO_{2peak}$  was not seen in our group of adolescents. Possible reasons for these findings could be that some of the adolescents had to stop the test before completely reaching full exhaustion. No significant improvement of  $VO_{2peak}$  at post-assessment could also be a consequence of type two error.<sup>20</sup>

In the present study, there was no change in EILV or EELV. An increase in EELV is associated with EFL and a breathing strategy with extra work of breathing (WOB) due to reduced inspiratory muscle endurance.<sup>6</sup> As EELV increases so does the degree of EFL.<sup>6</sup> When exercise intensity increases, EILV should increase.<sup>6</sup> Failure to increase EILV as exercise intensity increases are related to a breathing strategy with an increased BF which can further increase EFL.<sup>6</sup> The adolescents had no change of either EELV or EILV which could have played a part in why there was no EFL in adolescents at post-assessment.

ExtFVL/MFVL-analysis used in the present study has been an advantage this study in terms of visualization of degrees of EFL.<sup>6</sup> However, extFVL/MFVL-analysis is not yet a well-established method and there are a few studies to compare these results with. Time prior to practicing IB maneuver should be taken regarding the correct placement of extFVL within MFVL.<sup>6</sup> Also, consideration in the method for calculation in BR should be important. Use of  $FEV_1$  multiplied with 35 is also easier to calculate through the CPET testing.<sup>15</sup> However,  $FEV_1$  does not always pick up the change in the improvement of MVV in some individuals, as noted by Hallstrand, Bates and Schoene.<sup>17</sup>

The study has limitations due to low sample size. Also, the single pre-post design is considered a weak research design since there is no random allocation of participants.<sup>20</sup> Hence, further research of changes in EFL and BR in adolescents with asthma is required. Almost all adolescents either remained at no EFL or decreased their EFL at  $VO_{2peak}$ , which could indicate that EFL and BR in adolescents with asthma and exercise are safe to assessing further in a randomized controlled trial with more participants, along with proper medication.

In conclusion, the present study shows that BR remains low and there is no change and findings of EFL after a 10-week exercise intervention, in adolescents with asthma at  $VO_{2peak}$ , compared with the baseline assessment.



**Author affiliations:**

<sup>1</sup>University of Oslo

<sup>2</sup> University of Agder

<sup>3</sup> Norwegian School of Sport Science

**Acknowledgment:** I acknowledge the Norwegian Association for Asthma and Allergy for the financial support would like to thank supervisor and project leader Thomas Westergren, allowing access to this project. Joakim Sigdestad has been doing a great job with plotting and Oddbjørn has been helpful with assistance with testing.

**Contributors** AN conceived the research question, collected data, performed the data analysis, interpretation of findings and wrote the manuscript. TW, JS, and TS contributed to the study design. TW and JS contributed to data analysis and interpretation of findings and critically reviewed the manuscript. KRT, TS contributed along with AN with the collection of data. TW and TS were responsible for all data collected and provided access to the data. AN was granted full access to all study data and takes responsibility for the integrity of the data and the accuracy of the data analysis. NAAF did not play a role in the design, analysis or interpretation of results.

**Funding:** The main project (PLAY) which this present study is a subproject of, received funding from the research fund for asthma and allergy in the Norwegian Association for Asthma and Allergy (NAAF). However, AN did not receive any funding for this study.

**Competing interests:** None declared

**Patient consent for publication** Not required.

**Ethics approval** The regional ethical committee approved this study

**Data sharing** No additional data are available due to privacy and confidentiality laws.

**REFERENCES**

1. Papadopolous NG, Arakawa H, Carlsen KH, et al. International Consensus on (ICON) pediatric asthma. *Allergy* 2012;67(8): 976-997 doi: 10.1111/j.1398-9995.2012.02865.x.

2. Wanrooij VH, Willeboordse M, Dompeling E et al. Exercise training in children with asthma: a systematic review. *Br J Sports Med.* 2014;48 (13):1024-313 doi: 10.1136/bjsports-2012-091347
3. Del Giacco SR, Firinu D, Bjermer L et al. Exercise and asthma: an overview. *Eur Respir J* 2015;2:27984 doi: 10.3402/ecrj.v2.27984
4. William B, Hoskins G, Pow J et al. Low exercise among children with asthma: a culture of protection? A qualitative study of experiences and beliefs. *Br J Gen Pract* 2010; 60(577): 319-326 doi: 10.3399/bjgp10X515070.
5. Babb TG. Exercise Ventilatory Limitation: The Role of Expiratory Flow Limitation. *Exerc Sports Sci Rev* 2013;41(1):11-8 doi: 10.1097/JES.0b013e318267c0d2
6. Johnson BD, Weisman IM, Zeballos RJ et al. Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. *Chest* 1999; 116 (2): 488-503 doi:10.1378/chest.116.2.488
7. Nourry C, Deruelle F, Fabre C, Baquet G et al. Evidence of Ventilatory Constraints in Healthy Exercising Prepubescent Children. *Pediatr Pulmonol* 2006;41:133-140. doi: 10.3389/fphys.2019.00020
8. Swain K, Rosenkranz S, Beckman B et al. Expiratory flow limitation during exercise in prepubescent boys and girls: prevalence and implications. *J Appl Physiol* 2010;108 (5):1267-1274. doi: 10.1152/japplphysiol.00123.2009
9. Larsen, KO. Belastningsundersøkelse for vurdering av kardiopulmonar funksjon. *Hjerteforum* 2011;24: 17-25
10. Takken T, Bongers B, van Brussel M et al. Cardiopulmonary Exercise Testing in Pediatrics. *Ann Am Thorac Soc.* 2017;14(1):123-128. doi: 10.1513/AnnalsATS.201611-912FR.
11. Cole T, Flegal K, Nicholls D and Jackson A. Body mass index cut offs to define thinness in children and adolescents: international survey. *BMJ* 2007;335(7612):194. doi: 10.1136/bmj.39238.399444.55

12. Marinov B, Kostaniev S and Turnovska, T. Modified Treadmill Protocol for Evaluation of Physical Fitness in Pediatric Age Group – Comparison with Bruce and Balke Protocols. *Acta Physiol Pharmacol Bulg* 2003;27(2-3):1-5
13. American Thoracic Society/American College of Chest Physicians. ATS/ACCP statement on Cardiopulmonary Exercise Testing. *Am J Crit Care Med* 2003;167(2): 211-277 doi: 10.1164/ajrccm.167.10.950
14. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40(6):1324-43 doi: 10.1183/09031936.00080312. Brusasco
15. Miller MR, Hankinson J, V, et al. Standardisation of spirometry. *Eur Respir J* 2005;26: 319-338 doi: 10.1183/09031936.05.00034805
16. Qoltech - Measurement of Health-Related Quality of Life & Asthma Control. Qoltech.co.uk. 2019 accessed from <http://www.qoltech.co.uk/acq.html> 12<sup>th</sup> of May 2019
17. Hallstrand TS Bates, PW and Schoene RB. Aerobic Conditioning in Mild Asthma Decreases the Hypernea of Exercise and Improves Exercise and Ventilatory Capacity. *Chest* 2000;118 (5):1460-1469 doi: 10.1378/chest.118.5.1460
18. Chung HL. Asthma in childhood: a complex, heterogeneous disease. *Korean J Pediatr* 2011;54 (1):1–5. doi:10.3345/kjp.2011.54.1.1
19. Philpott JF, Houghton K and Luke A. Physical activity recommendations for children with specific chronic health conditions: juvenile idiopathic arthritis, hemophilia, asthma, and cystic fibrosis. *Clin J Sports Med.* 2010; 20:167-172 doi: 10.1097/JSM.0b013e3181d2eddd
20. Carter R, and Lubinsky J. Rehabilitation research. Principle and Application. St. Louis, Miss: Elsevier Saunders 2016.p. 69-323
21. Gotshall RW. Airway response during exercise and Hyperpnea in Non-Asthmatics and Asthmatics Individuals. *Sports Medicine.* 2006;36(6): 573-527 doi:10.2165/00007256-200636060-0005

22. Vincent, WJ. Statistics in Kinesiology. Human Kinetics Publishers. Champaign, IL 2005  
p.61-105

**Appendix 1: Figures for article:**




Figure 1. Expiratory flow limitation before and after 10 weeks of exercise intervention with adolescents with asthma ( $n=15$ ).




Figure 2. Breathing reserve (%) before and after 10 weeks of exercise intervention in adolescents with asthma. ( $n=15$ )



# Part 3 Appendices for the master thesis

## Appendix 1: List of abbreviations

### Abbreviations

**EFL:** Expiratory flow limitation

**BR:** Breathing reserve

**PA:** Physical activity

**BHR:** Bronchial hyperresponsiveness

**EIB:** Exercise-induced bronchoconstriction

**extFVL:** tidal exercise flow-volume loop

**MFVL:** maximal flow-volume loop

**CPET:** Cardiopulmonary exercise test

**VE:** Minute ventilation

**MVV:** Maximal voluntary ventilation

**FEV<sub>1</sub>:** Forced expiratory volume in 1 second

**FVC:** Forced vital capacity

**BF:** Breathing frequency

**VC:** vital capacity

**VE:** minute ventilation

**VO<sub>2</sub>:** oxygen uptake

**VO<sub>2</sub>-peak:** Highest VO<sub>2</sub> achieved on a test performed to limit tolerance

**VT:** tidal volume

**EILV:** End- inspiratory lung volume

**EELV:** End-expiratory lung volume

**IC:** inspiratory capacity

**ATS:** American Thoracic Society

**ICON:** International consensus on Pediatric Asthma

## **Appendix 2a: Information letter of consent and consent form, for parents:**



**Forespørsel om deltakelse i forskningsprosjektet**

**PLAY (Physical activity and Asthma in Youth)**



Fysisk aktivitet er viktig for alle unge med astma, blant annet fordi god fysisk form er med på å kontrollere sykdommen og gi god helse. Hva som skal til for at ungdom med astma positivt mestrer en frisk og fysisk aktiv hverdag, vet man derimot for lite om.

Dette er derfor et spørsmål til deg om å la din ungdom delta i en forskningsstudie for å undersøke hvordan vi kan hjelpe unge med astma til en friskere og mer aktiv hverdag. Vi ønsker å finne ut hvordan vi i fremtiden kan gi bedre behandling til barn og unge med astma. Norges Idrettshøgskole (NIH) og Fakultet for helse- og idrettsvitenskap ved Universitetet i Agder (UiA) og er sammen ansvarlig for studien som gjennomføres i samarbeid med helsetjenesten på sykehus og i kommunen. Leder av prosjektet ved NIH er Førsteamanuensis Trine Stensrud.

Hva innebærer PROSJEKTET?

En lege med spesialisering i astma og allergi vil være medisinsk ansvarlig for studien.

Ungdommen din skal først gjennomgå en kondisjonstest. Denne testen utføres på Arbeidsfysiologisk testlab på NIH, første gang i løpet av november/desember. Testen går ut på at ungdommen skal gå og løpe i til sammen 15-20 minutter på en tredemølle, samtidig som det puster gjennom en maske. Mot slutten av testen vil ungdommen bli ordentlig sliten. Vi måler da hans/hennes maksimale oksygenopptak, som er et mål på kondisjon. I forbindelse med løpetesten vil vi også ta en liten blodprøve fra fingeren til din ungdom, og han/hun vil kjenne et lite stikk som kan være vondt, men raskt går over. Vi vil også før løps-testen måle lungefunksjon slik som dere er vant til fra legen og/eller sykehuset. I forbindelse med testen vil ungdommen også fylle ut et spørreskjema. Hele besøket på testlabben tar ca en time.

Ungdommen får også utlevert en måler som skal bæres rundt overarmen i 7 sammenhengende dager. Denne registrerer ungdommens daglige energiforbruk. Ungdommen vil gjennomgå kondisjonstesten på nytt og ha måleapparatet på i 7 dager, etter de første seks ukene og helt til slutt i studien. Deretter vil alle ungdommene delta i en aktivitetsgruppe på 15-20 ungdommer to ganger i uken tirsdag og torsdag kl. 18-19 over en periode på ti uker. Aktivitetsøktene vil bli ledet av forskere og studenter ved Norges Idrettshøgskole. Fokuset er at ungdommene skal ha det gøy når de er i aktivitet. Øktene vil være lystbetonte og lekpreget, men likevel ha en høy intensitet. Øktene vil foregå innendørs på Norges Idrettshøgskole.

En forsker vil være tilstede og observere testing og aktivitet, og vil også intervju din ungdom sammen med andre barn i grupper på inntil seks ved tre anledninger. Samtalene finner ikke

sted i gymsalen. Disse samtaler vil bli tatt opp på bånd, og forskeren vil gjøre notater fra sine observasjoner.

I prosjektet vil vi innhente og registrere opplysninger fra din ungdoms journal vedrørende astmasykdommen, symptomer og medisinsk behandling for å kartlegge grunnlaget for din ungdoms astmadiagnose.

### **Mulige fordeler og ulemper**

Det utbetales ingen honorar for å være med i studien, og tilbudet er gratis.

Gjennom studien vil ungdommen få muligheten til å være i aktivitet sammen med andre ungdommer med astma, og forbedre sin fysiske kondisjon gjennom lystbetonte aktiviteter. Fysisk aktivitet kan også trigge ubehagelige symptomer og tett pust. Derfor vil vi at din ungdom gjennom hele prosjektet skal bruke sine medisiner som legen har foreskrevet, og den lege som er medisinsk ansvarlig vil også være tilgjengelig for råd og veiledning ved behov. Intervjuene som gjennomføres vil også åpne for refleksjon om egen situasjon og egen helse. Samtidig kan slike samtaler bli personlige. Det er derfor viktig at din ungdom selv er bevisst på hva hun/han deler og ikke. Du og din ungdom vil også bruke tid på å være med i studien. I tillegg til de to ukentlige øktene over tolv uker vil dere bruke opptil en time i forbindelse med tester før og etter studien, og opp til en time til intervju ved tre tilfeller i løpet av perioden. Intervjuene vil bli samordnet med øktene og/eller testingen.

### **Frivillig deltakelse og mulighet for å trekke sitt samtykke**

Det er frivillig å delta i studien. Du eller din ungdom kan når som helst og uten å oppgi noen grunn trekke deres samtykke til å delta i studien. Dette vil ikke få konsekvenser for videre behandling eller oppfølging hos lege eller ved sykehuset. Dersom du ønsker at din ungdom skal delta, undertegner du og din ungdom samtykkeerklæringen på siste side. Om du nå sier ja til at din ungdom kan delta, kan du senere ombestemme deg og trekke tilbake ditt samtykke uten at det påvirker din eller din ungdoms øvrige behandling. Hvis din ungdom underveis velger å trekke seg fra aktivitetsopplegget men likevel opprettholder sitt samtykke til å være med på intervjuene er det tilrettelagt for det. Dersom du eller din ungdom senere ønsker å trekke dere eller har spørsmål til studien, kan dere kontakte Trine Stensrud, tlf 23262346 (e-post: trine.stensrud@nih.no) eller Julie Stang, tlf 23262244 (e-post: julie.stang@nih.no), ved Norges Idrettshøgskole.

### **Hva skjer med informasjonen om deg?**

Testresultatene og informasjonen som registreres skal kun brukes slik som beskrevet i hensikten med studien. Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennerlige opplysninger. En kode knytter din ungdoms opplysninger til en navneliste. Samtaler som blir tatt opp på bånd, vil bli skrevet ut som en tekst, og i den forbindelse samt i notater vil alle navn bli byttet ut. Det vil ikke være mulig å gjenkjenne ungdommen ved navn eller stemme uten og direkte høre på båndopptaket.

Det er kun autorisert personell knyttet til prosjektet som har adgang til båndopptaket, eller til navnelisten, og som kan finne tilbake til din ungdom.

Det vil ikke være mulig for utenforstående å identifisere din ungdom i resultatene av studien når disse publiseres. Opptak og andre opplysninger som kan knyttes til ditt barn vil slettes senest 31.12.2022.

### **Forsikring**

Norges Idrettshøgskole er en statlig institusjon og er således selvassurandør.

### **Godkjenning**

Prosjektet er godkjent av Regional komite for medisinsk og helsefaglig forskningsetikk, saksnr. hos REK (2017/1320).

## Samtykke til deltakelse i PROSJEKTET

### Jeg er villig til å delta i prosjektet

|              |                    |
|--------------|--------------------|
| Sted og dato | Deltakers signatur |
|--------------|--------------------|

|                                     |
|-------------------------------------|
| Deltakers navn med trykte bokstaver |
|-------------------------------------|

Som foresatte til \_\_\_\_\_ (Fullt navn) samtykker vi til at hun/han kan delta i prosjektet

|              |                     |
|--------------|---------------------|
| Sted og dato | Foresattes signatur |
|--------------|---------------------|

|                                      |
|--------------------------------------|
| Foresattes navn med trykte bokstaver |
|--------------------------------------|

|              |                     |
|--------------|---------------------|
| Sted og dato | Foresattes signatur |
|--------------|---------------------|

|                                      |
|--------------------------------------|
| Foresattes navn med trykte bokstaver |
|--------------------------------------|

Jeg bekrefter å ha gitt informasjon om prosjektet

|              |          |
|--------------|----------|
| Sted og dato | Signatur |
|--------------|----------|

|                    |
|--------------------|
| Rolle i prosjektet |
|--------------------|

**Appendix 2B, information letter and consent form, version for participants**

## Forespørsel om deltakelse i forskningsprosjektet

# PLAY (Physical activity and Asthma in Youth)

### Hvorfor gjør vi dette?

Dette er et spørsmål til deg som har astma om å delta i en undersøkelse om hva som kan tilrettelegge for en positiv deltakelse i fysisk aktivitet. Vi ønsker å finne ut hvordan vi kan hjelpe unge med astma til en friskere og mer aktiv hverdag. Fakultet for helse- og idrettsvitenskap ved Universitetet i Agder (UiA) og Norges Idrettshøgskole (NIH) er ansvarlig for prosjektet som gjennomføres i samarbeid med helsetjenesten i kommunen og på sykehus.

### Hva innebærer studien?

Det første som skjer hvis du blir med er at du skal gjennomføre en test på Norges Idrettshøgskole på Sognsvann hvor du skal først gå, og så løpe på en tredemølle i til sammen ca. 15-20 minutter. På slutten av løpetesten blir du skikkelig sliten. I forbindelse med løpetesten vil vi også ta en liten blodprøve fra fingeren din, og du vil kjenne et lite stikk som kan være vondt, men raskt går over. Når du går og løper måler vi kondisjonen din ved at du puster gjennom en maske. Før du løper vil vi også måle lungefunksjonen din ved at du blåser det du kan i masken slik som du tidligere har gjort gjennom et munnstykke hos din lege eller på sykehuset. Videre vil du få utdelt en måler som du skal ha rundt den ene overarmen. Denne måler den daglige aktiviteten din, og du skal ha den på deg i 7 dager etter hverandre og gjøre det du pleier å gjøre. Før du går hjem fra testen skal du også fylle ut et spørreskjema.

Deretter skal du være med i en aktivitetsgruppe to ganger i uken i ti uker. Etter aktivitetsperiodene er slutt skal du gå og løpe på tredemølla og testes en gang til.

Aktivitetsgruppa du skal være med i vil bestå av 15-20 andre ungdommer på din alder, og aktiviteten vil foregå inne på Norges Idrettshøgskole på Sognsvann tirsdag og torsdag kl. 18-19. Aktivitetene vil være gøyale samtidig som du blir sliten. Aktivitetene blir ledet av trenere fra Norges Idrettshøgskole.

En forsker som ikke er trener vil være tilstede for å bli litt kjent med deg og aktivitetene du er med på. Han/hun vil også gjennomføres samtaler med deg og andre ungdommer i grupper på fem-seks ungdommer. Disse samtalene finner ikke sted i gymsalen. Det vil bli gjort lydopptak av disse samtalene.

Informasjon om din astma og din behandling fra din legejournal vil også bli innhentet i prosjektet.

### **Mulige fordeler og ulemper**

Gjennom studien vil du få muligheten til å være i aktivitet sammen med andre ungdommer med astma, og forbedre din kondisjon gjennom gøy aktivitet. Fysisk aktivitet kan også trigge ubehagelige symptomer og tett pust. Derfor vil vi at du hele tiden skal bruke dine medisiner som din lege har foreskrevet, og en lege vil være tilgjengelig for råd og veiledning ved behov som medisinsk ansvarlig.

Samtalene med forskeren i grupper vil handle om din opplevelse av din hverdag med astma. Slike samtaler kan bli personlige. Det er derfor viktig at du selv bestemmer hva du vil fortelle til de andre og til forskeren.

Du vil bruke tid på å være med i studien. I tillegg til trening to kvelder i uken i tolv uker vil det ta omtrent en time når vi skal teste din kondisjon før og etter aktivitetsperioden. Hver gruppesamtale med forskeren vil vare i en time og vi skal ha tre samtaler i løpet av perioden. Samtalene vil være rett før eller etter en av treningene.

### **Hva skjer med det vi får vite om deg?**

Det vi får vite om deg skal kun brukes for å finne ut hvordan vi kan hjelpe unge med astma til en friskere og mer aktiv hverdag. Alle opplysninger vi får vite om deg vil registreres med et kodenummer, ikke navn og fødselsnummer. I et låst arkivskap oppbevares informasjon om hvem som har hvilket kodenummer. I samtalene som blir tatt opp på bånd vil alle navn bli byttet ut når vi skriver ut samtalene som tekst. Det vil heller ikke være mulig å gjenkjenne din stemme uten og direkte høre på båndopptaket.

Det er kun forskere i prosjektet som har adgang til båndopptaket, den hemmelige koden og til navnelisten som kan finne tilbake til deg. Det vil ikke være mulig for andre enn forskerne å finne igjen deg i resultatene av studien når disse skal presenteres. Men alle som er med vil kanskje kunne huske å kjenne igjen ting hvis dere leser om det etterpå. Opptak og andre opplysninger som kan knyttes til deg vil slettes senest 31.12.2022.

### **Vil du være med?**

Det er frivillig å være med. Om du ombestemmer deg og finner ut at du ikke har lyst å være med lenger, er det helt greit. Det vil ikke ha noe å si for din oppfølging på sykehuset, hos helsesøster eller din lege. Dersom du ønsker å delta, skriver du ditt navn på siste side i skjemaet som dine foreldre/foresatte har fått. Om du slutter på aktivitetene men vil være med på samtalene i gruppe kan du det. Hvis du har spørsmål til oss, kan du gjerne ringe eller sende e-post. Telefonnummer og e-post står nederst på arket.

Vennlig hilsen,

---

Anette Nielsen (Masterstudent)  
Tlf 48033629

---

Kristine Ringsjø Tufte (Masterstudent)  
984 48 365

[anette.nielsen@studmed.uio.no](mailto:anette.nielsen@studmed.uio.no)

[kr.tufte@hotmail.com](mailto:kr.tufte@hotmail.com)

### Appendix 3: Regional ethical committee approval



| Region:     | Saksbehandler: | Telefon: | Vår dato:   | Vår referanse:   |
|-------------|----------------|----------|-------------|------------------|
| REK sør-øst | Mariann Glenna | 22845526 | 19.09.2017  | 2017/1320        |
|             | Daidsen        |          |             | REK sør-øst B    |
|             |                |          | Deres dato: | Deres referanse: |
|             |                |          | 13.06.2017  |                  |

Vår referanse må oppgis ved alle henvendelser

Sveinung Berntsen Stølevik  
Universitetet i Agder

### 2017/1320 Fysisk aktivitet og astma hos ungdom

**Forskningsansvarlig:** Universitetet i Agder

**Prosjektleder:** Sveinung Berntsen Stølevik

Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK sør-øst) i møtet 23.08.2017. Vurderingen er gjort med hjemmel i helseforskningsloven (hfl.) § 10.

#### Prosjektleders prosjektbeskrivelse

«Hensikten med prosjektet er å utvikle, gjennomføre og evaluere to treningsintervensjoner med gruppetrening med høy intensitet og lekbetonte aktiviteter som er lette å mestre for ungdom med astma henholdsvis i alderen 13-16 år og 16-19 år, og å undersøke hvordan det endrer selvforståelse, motivasjon for trening, nivå av fysisk aktivitet, fysisk form, helserelatert livskvalitet, astmakontroll og ventilatorisk flowbegrensning under anstrengelse. Studien har et mixed-methods design som inkluderer klinisk testing av lungefunksjon og fysisk form, validerte instrumenter for motivasjon, livskvalitet og astmakontroll, registrering av treningsintensitet ved puls, objektiv fysisk aktivitet ved bruk av aktivitetsmonitor, og kvalitative data fra deltakere basert på fokusgruppeintervjuer og

*feltobservasjoner av trening og testing. Basert også på registrering av aktiviteter, oppmøte og gjennomføring vil det bli lagt et kunnskapsgrunnlag for en randomisert kontrollert studie etter tilsvarende mønster»*

## Komiteens vurdering

Dette er en masteroppgave som har som formål å øke kunnskap om hvordan en treningsintervensjon, med tanke på ungdommer med astma, kan gjennomføres i ungdommenes lokalmiljø. Prosjektet vil også kunne bidra til å kartlegge endring av adferd, mestring og motivasjon spesifikt for denne pasientgruppen, samt hvordan dette kan påvirke aktivitetsnivå, sykdomsaktivitet og livskvalitet.

Ved inklusjon vil det bli gjennomgått journaler og/eller utført objektive tester for verifisering av astmadiagnosen hos samarbeidende fastleger, privatpraktiserende spesialister og sykehus, avhengig av hvor deltakerne rekrutteres fra. Det skal også innhentes nye helseopplysninger fra tester og undersøkelser i forbindelse med astma diagnosen; lungefunksjon, hjertefrekvens og laktet prøve av kapillær. Deltakerne skal i tillegg fylle ut spørreskjema om livskvalitet, utføre treningsøvelser og gjennomføre fokusgruppeintervju.

Det er lagt opp til at deltakerne skal møte to ganger per uke i 12 uker for gjennomføring av studien.

Alle tester og undersøkelser vil være i tråd med vanlig standard behandling.

---

Besøksadresse:  
Gullhaugveien 1-3, 0484 Oslo

Telefon: 22845511  
E-post: [post@helseforskning.etikk.no](mailto:post@helseforskning.etikk.no)  
Web: <http://helseforskning.etikk.no/>

All post og e-post som inngår i  
saksbehandlingen, bes adressert til REK  
sør-øst og ikke til enkelte personer

Kindly address all mail and e-mails to  
REK the Regional Ethics Committee, REK  
sør-øst, not to individual staff

## Samtykke/rekruttering

Samtykke vil bli innhentet fra foreldre til barn i alderen 13-15 år, og fra deltakerne selv i alderen 16-18 år.

Aktuelle deltakerne vil bli identifisert gjennom samarbeid med skolehelsetjenesten, fastleger, privatpraktiserende spesialister og offentlige sykehus. Samarbeidende instanser vil på vegne av prosjektet informere deltakere (13-18 år) og foreldre (13-15 år), og de som ønsker det kan få mer utfyllende informasjon og samtykkeskriv fra prosjektmedarbeidere.

Komiteen har ingen innvendinger til at prosjektet gjennomføres slik det fremstilles.

## Vedtak

Komiteen godkjenner prosjektet i henhold til helseforskningsloven § 9 og § 33.

Godkjenningen er gitt under forutsetning av at prosjektet gjennomføres slik det er beskrevet i søknaden.

Tillatelsen gjelder til 31.12.2022. Av dokumentasjonshensyn skal opplysningene likevel bevares inntil 31.12.2027. Opplysningene skal lagres aidentifisert, dvs. atskilt i en nøkkel- og en opplysningsfil. Opplysningene skal deretter slettes eller anonymiseres, senest innen et halvt år fra denne dato.



Forskningsprosjektets data skal oppbevares forsvarlig, se personopplysningsforskriften kapittel 2, og Helsedirektoratets veileder «*Personvern og informasjonssikkerhet i forskningsprosjekter innenfor helse- og omsorgssektoren*»

### **Sluttmelding og søknad om prosjektendring**

Prosjektleder skal sende sluttmelding til REK sør-øst på eget skjema, jf. hfl. § 12.

Prosjektleder skal sende søknad om prosjektendring til REK sør-øst dersom det skal gjøres vesentlige endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.

### **Klageadgang**

Du kan klage på komiteens vedtak, jf. forvaltningslovens § 28 flg. Klagen sendes til REK sør-øst B. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK sør-øst B, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.

Komiteens avgjørelse var enstemmig.

Med vennlig hilsen

Ragnhild Emblem  
professor, dr. med. leder  
REK sør-øst B

Mariann Glenna Davidsen  
rådgiver

**Kopi til:**

**- Universitetet i Agder ved øverste administrative ledelse**

## **Appendix 4: Figures and tables for the introductory review**




Figure 1. Ventilatory changes from rest (A) and exercise (B). Taken with permission from: *Exercise and Sport Sciences Reviews*, Volume 41 Issue 1. Tony Babb. Exercise Ventilatory Limitation: The Role of Expiratory Flow Limitation. p. 14.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529766>




Figure 2: The difference in breathing pattern and EELV when the MVV maneuver is performed (left) relative to the same persons at peak exercise intensity (right). Reprinted from *CHEST*. Bruce D. Johnson, Idelle M. Weisman, Jorge R Zeballos, Ken C Beck. Emerging Concepts in the Evaluation of Ventilatory limitation During Exercise: the exercise tidal flow volume-loop. Volume 116, Issue 2 p. 493 Copyright (1999) with permission from Elsevier.

## Appendix 5: Submission guidelines for BMJ Open Respiratory Research

### Original Research

Original Research should follow the basic structure of Abstract, Introduction, Methods, Results, Discussion, References, and tables and figures as appropriate.

**Word count:** up to 4000

**Abstract:** up to 300

**Tables/Illustrations:** up to 5

**References:** up to 100

## Formatting checklist

1. **Author information:** Have you got an [ORCID iD](#) (from the 28th November 2018 a majority of BMJ Journals will be mandating ORCID iDs for all submitting authors at the time of article submission). Have you provided details of all of your co-authors? Is the information that you have entered into ScholarOne the same as the information on the manuscript title page?
2. **Manuscript length and formatting:** Have you provided your abstract in the correct format? Have you supplied any required additional information for your article type, such as key messages? Have you checked that your manuscript doesn't exceed the requirements for word count, number of tables and/or figures, and number of references?
3. **Tables:** Are your tables in an editable format? Have you embedded them into the main word document? Have they been cited in the text? Have you provided appropriate table legends? Have you uploaded any lengthy tables as supplementary files for online publication?
4. **Figures:** Have you uploaded figures separately from the text? Have they been supplied in an acceptable format and are they of sufficient quality? Are they suitable for black and white reproduction (unless you intend to pay any required fees for colour printing)? Have the files been labelled appropriately? Have the figures been cited in the text? Have you provided appropriate figure legends?
5. **References:** Have all of the references been cited in the text?
6. **Supplementary files:** Have you supplied these in an acceptable format? Have they been cited in the main text?
7. **Statements:** Have you included the necessary statements relating to [author contributorship](#), [competing interests and funding](#), [data sharing](#), [patient consent](#) and [ethical approval](#)?
8. **Acknowledgements:** Have you acknowledged all contributors who do not meet the criteria for authorship? Have you acknowledged if your work has been previously presented at a conference/published as a conference abstract?
9. **Suggested reviewers:** Have you suggested reviewers for your paper (if required by the journal)?
10. **Research reporting checklists:** Have you either provided the appropriate statement for your study type, or explained why a checklist isn't required?

11. **Reproducing figures:** Have you [obtained permission from the copyright holder](#) to re-use any previously published material? Has the source been acknowledged?

## Title page

This is excluded for the journal *BMJ Quality and Safety* which operates triple-blind peer review.

The title page must contain the following information:

- Title of the article.
- Full name, postal address, e-mail and telephone number of the corresponding author.
- Full name, department, institution, city and country of all co-authors.
- Word count, excluding title page, abstract, references, figures and tables.
- 

## Keywords

Authors can usually opt to (or are required to) choose keywords relevant to the content of the manuscript during the submission process. This assists in the identification of the most suitable reviewers for the manuscript. The selected keywords should also be included in the abstract itself.

The manuscript must be submitted as a Word document. PDF is not accepted.

The manuscript should be presented in the following order:

- Title page.
  - Abstract, or a summary for case reports (Note: references should not be included in abstracts or summaries).
  - Main text separated under appropriate headings and subheadings using the following hierarchy: BOLD CAPS, bold lower case, Plain text, Italics.
  - Tables should be in Word format and placed in the main text where the table is first cited. Tables should also be cited in numerical order.
  - Acknowledgments, Competing Interests, Funding and all other required statements.
  - References. All references should be cited in the main text in numerical order.
- Figures must be uploaded as separate files (view further details under the Figures/illustrations section). All figures must be cited within the main text in numerical order and legends should be provided at the end of the manuscript.

Online Supplementary materials should be uploaded using the File Designation “Supplementary File” on the submission site and cited in the main text. Please remove any hidden text headers or footers from your file before submission.

## Style

Acronyms and abbreviations should be used sparingly and fully explained when first used. Abbreviations and symbols must be standard. SI units should be used throughout, except for blood pressure values which should be reported in mm Hg.

Whenever possible, drugs should be given their approved generic name. Where a proprietary (brand) name is used, it should begin with a capital letter.

## Figures/illustrations

Images must be uploaded as separate files. All images must be cited within the main text in numerical order and legends must be provided (ideally at the end of the manuscript).

### Colour images and charges

For certain journals, authors of unsolicited manuscripts that wish to publish colour figures in print will be charged a fee to cover the cost of printing. Refer to the specific journal’s instructions for authors for more information.

Alternatively, authors are encouraged to supply colour illustrations for online publication and black and white versions for print publication. Colour publication online is offered at no charge, but the figure legend must not refer to the use of colours.

[Detailed guidance on figure preparation](#)

### File types

Figures should be submitted in TIFF, EPS, JPEG or PDF formats. In EPS files, text (if present) should be outlined. For non-vector files (eg TIFF, JPEG) a minimum resolution of 300 dpi is required, except for line art which should be 1200 dpi. Histograms should be presented in a simple, two-dimensional format, with no background grid.

For figures consisting of multiple images/parts, please ensure these are submitted as a single composite file for processing. We are unable to accept figures that are submitted as multiple files.

During submission, ensure that the figure files are labelled with the correct File Designation of “Mono Image” for black and white figures and “Colour Image” for colour figures.

Figures are checked using automated quality control and if they are below the minimum standard you will be alerted and asked to resupply them.

Please ensure that any specific patient/hospital details are removed or blacked out (e.g. X-rays, MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are NOT accepted.

## Tables

Tables should be in Word format and placed in the main text where the table is first cited.

Tables must be cited in the main text in numerical order. Please note that tables embedded as

Excel files within the manuscript are NOT accepted. Tables in Excel should be copied and pasted into the manuscript Word file.

Tables should be self-explanatory and the data they contain must not be duplicated in the text or figures. Any tables submitted that are longer/larger than 2 pages will be published as online only supplementary material.

## References

Authors are responsible for the accuracy of cited references and these should be checked before the manuscript is submitted.

### Citing in the text

References must be numbered sequentially as they appear in the text. References cited in figures or tables (or in their legends and footnotes) should appear at the end of the reference list to avoid re-numbering if tables and figures are moved around at peer review/proof stage. Reference numbers in the text should be inserted immediately after punctuation (with no word spacing)—for example,[6] not [6].

Where more than one reference is cited, these should be separated by a comma, for example,[1, 4, 39]. For sequences of consecutive numbers, give the first and last number of the sequence separated by a hyphen, for example,[22-25]. References provided in this format are translated during the production process to superscript type, and act as hyperlinks from the text to the quoted references in electronic forms of the article.

Please note that if references are not cited in order the manuscript may be returned for amendment before it is passed on to the Editor for review.

### Preparing the reference list

References must be numbered consecutively in the order in which they are mentioned in the text.

Only papers published or in press should be included in the reference list. Personal communications or unpublished data must be cited in parentheses in the text with the name(s) of the source(s) and the year. Authors should request permission from the source to cite unpublished data.

Journals from BMJ use a slightly modified version of Vancouver referencing style (see example below). Note that [The BMJ](#) uses a different style.

### [BMJ reference style](#)

List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and add 'et al.' (The exception is the Journal of Medical Genetics, which lists all authors). Use one space only between words up to the year and then no spaces. The journal title should be in italic and abbreviated according to the style of Medline. If the journal is not listed in Medline then it should be written out in full.

[Check journal abbreviations using PubMed](#)

[Check citation information using PubMed](#)

### Example references

Journal article

13 Koziol-McLain J, Brand D, Morgan D, et al. Measuring injury risk factors: question reliability in a statewide sample. *Inj Prev* 2000;6:148–50.

Chapter in book

14 Nagin D. General deterrence: a review of the empirical evidence. In: Blumstein A, Cohen J, Nagin D, eds. *Deterrence and Incapacitation: Estimating the Effects of Criminal Sanctions on Crime Rates*. Washington, DC: National Academy of Sciences 1978:95–139.

## **Book**

15 Howland J. Preventing Automobile Injury: New Findings From Evaluative Research. Dover, MA: Auburn House Publishing Company 1988:163–96.

## **Abstract/supplement**

16 Roxburgh J, Cooke RA, Deverall P, et al. Haemodynamic function of the carbomedics bileaflet prosthesis [abstract]. *Br Heart J* 1995;73(Suppl 2):P37.

## **Electronic citations**

Websites are referenced with their URL and access date, and as much other information as is available. Access date is important as websites can be updated and URLs change. The “date accessed” can be later than the acceptance date of the paper, and it can be just the month accessed.

## **Electronic journal articles**

Morse SS. Factors in the emergency of infectious diseases. *Emerg Infect Dis* 1995 Jan-Mar;1(1). [www.cdc.gov/nciod/EID/vol1no1/morse.htm](http://www.cdc.gov/nciod/EID/vol1no1/morse.htm) (accessed 5 Jun 1998).

## **Electronic letters**

Bloggs J. Title of letter. *Journal name* Online [eLetter] Date of publication. url eg: Krishnamoorthy KM, Dash PK. Novel approach to transseptal puncture. *Heart* Online [eLetter] 18 September 2001. <http://heart.bmj.com/cgi/eletters/86/5/e111#EL1>

## **Legal material**

Toxic substances Control Act: Hearing on S776 Before the Subcommittee of the Environment of the Senate Comm. on Commerce, 94th Congress 1st September (1975).

Washington v Glucksberg 521 US 702 (1997)

## **Law references**

The two main series of law reports, Weekly Law Reports (WLR) and All England Law Reports (All ER) have three volumes a year.

For example:

Robertson v Post Office [1974] 1 WLR 1176

Ashcroft v Mersey Regional Health Authority [1983] 2 All ER 245

R v Clarence [1868] 22 QBD 23

Wimpey Construction UK Ltd v Poole (1984) Times, 3 May

There are good historical precedents for the use of square and round brackets. Since 1891, round ones have referred to the date of the report, square ones to the date of publication of the report. Apart from not italicising the name of the case, we use the lawyers’ style; be careful with punctuation. Here are some more examples:

Caparo Industries plc v Dickman and others [1990] 1 All ER 568-608.

R v Clarence [1888] 22 QBD 23.

Finlayson v HMAdv 1978 SLT (Notes) 60

Block v Martin (1951) 4 DLR 121

Official Journal of the European Communities: at the top of the page it gives the No, vol, and page and, at the other side of the header, the date.

The abbreviation for the title is given in parentheses under the title. Jiggle these elements around to get, eg:

Council Directive of 14 June 1989. Official Journal of the European Communities No L 1989 June 28:181/44-6. (89/831/EEC).

## **Digital Object Identifier (DOI)**

A DOI is a unique string created to identify a piece of intellectual property in an online environment and is particularly useful for articles that are published online before appearing in print (and therefore have not yet been assigned the traditional volume, issue and page number references). The DOI is a permanent identifier of all versions of an article, whether



raw manuscript or edited proof, online or in print. Thus the DOI should ideally be included in the citation even if you want to cite a print version of an article.

#### **How to cite articles with a DOI before they have appeared in print**

1. Alwick K, Vronken M, de Mos T, et al. Cardiac risk factors: prospective cohort study. *Ann Rheum Dis* Published Online First: 5 February 2004. doi:10.1136/ard.2003.001234

#### **How to cite articles with a DOI once they have appeared in print**

1. Vole P, Smith H, Brown N, et al. Treatments for malaria: randomised controlled trial. *Ann Rheum Dis* 2003;327:765–8 doi:10.1136/ard.2003.001234 [published Online First: 5 February 2002].

PLEASE NOTE: RESPONSIBILITY FOR THE ACCURACY AND COMPLETENESS OF REFERENCES RESTS ENTIRELY WITH THE AUTHOR.

## **Appendix 6: Permission to use figures:**

### **WOLTERS KLUWER HEALTH, INC. LICENSE TERMS AND CONDITIONS**

May 13, 2019

---

This Agreement between Anette Nielsen ("You") and Wolters Kluwer Health, Inc. ("Wolters Kluwer Health, Inc.") consists of your license details and the terms and conditions provided by Wolters Kluwer Health, Inc. and Copyright Clearance Center.

License Number

4586621047790

|  |  |
|--|--|
| License date                           | May 12, 2019   |
| Licensed Content Publisher             | Wolters Kluwer Health, Inc.  |
| Licensed Content Publication           | Exercise and Sport Sciences Reviews  |
| Licensed Content Title                 | Exercise Ventilatory Limitation: The Role of Expiratory Flow Limitation  |
| Licensed Content Author                | Tony Babb  |
| Licensed Content Date                  | Jan 1, 2013  |
| Licensed Content Volume                | 41   |
| Licensed Content Issue                 | 1  |
| Type of Use                            | Dissertation/Thesis  |
| Requestor type                         | Individual   |
| STM publisher name                     |  |
| Portion                                | Figures/table/illustration   |
| Number of figures/tables/illustrations | 1  |
| Figures/tables/illustrations used      | Figure 1   |
| Author of this Wolters Kluwer article  | No   |
| Title of your thesis / dissertation    | Changes in breathing reserve and expiratory flow limitation at peak exercise intensity after a 10-weeks exercise intervention in adolescents with asthma |
| Expected completion date               | May 2019   |
| Estimated size(pages)                  | 1  |
| Requestor Location                     | Anette Nielsen<br>*****<br><br>Oslo, other<br>Norway<br>Attn:  |
| Total                                  | 0.00 USD   |
| Terms and Conditions                   |  |

### **Wolters Kluwer Health Inc. Terms and Conditions**

1. **Duration of License:** Permission is granted for a one time use only. Rights herein do not apply to future reproductions, editions, revisions, or other derivative works. This permission shall be effective as of the date of execution by the parties for the maximum period of 12 months and should be renewed after the term expires.
  - i. When content is to be republished in a book or journal the validity of this agreement should be the life of the book edition or journal issue.
  - ii. When content is licensed for use on a website, internet, intranet, or any publicly accessible site (not including a journal or book), you agree to remove the material from such site after 12 months, or request to renew your permission license
2. **Credit Line:** A credit line must be prominently placed and include: For book content: the author(s), title of book, edition, copyright holder, year of publication; For journal content: the author(s), titles of article, title of journal, volume number, issue number,

- inclusive pages and website URL to the journal page; If a journal is published by a learned society the credit line must include the details of that society.
3. **Warranties:** The requestor warrants that the material shall not be used in any manner which may be considered derogatory to the title, content, authors of the material, or to Wolters Kluwer Health, Inc.
  4. **Indemnity:** You hereby indemnify and hold harmless Wolters Kluwer Health, Inc. and its respective officers, directors, employees and agents, from and against any and all claims, costs, proceeding or demands arising out of your unauthorized use of the Licensed Material
  5. **Geographical Scope:** Permission granted is non-exclusive and is valid throughout the world in the English language and the languages specified in the license.
  6. **Copy of Content:** Wolters Kluwer Health, Inc. cannot supply the requestor with the original artwork, high-resolution images, electronic files or a clean copy of content.
  7. **Validity:** Permission is valid if the borrowed material is original to a Wolters Kluwer Health, Inc. imprint (J.B Lippincott, Lippincott-Raven Publishers, Williams & Wilkins, Lea & Febiger, Harwal, Rapid Science, Little Brown & Company, Harper & Row Medical, American Journal of Nursing Co, and Urban & Schwarzenberg - English Language, Raven Press, Paul Hoeber, Springhouse, Ovid), and the Anatomical Chart Company
  8. **Third Party Material:** This permission does not apply to content that is credited to publications other than Wolters Kluwer Health, Inc. or its Societies. For images credited to non-Wolters Kluwer Health, Inc. books or journals, you must obtain permission from the source referenced in the figure or table legend or credit line before making any use of the image(s), table(s) or other content.
  9. **Adaptations:** Adaptations are protected by copyright. For images that have been adapted, permission must be sought from the rightsholder of the original material and the rightsholder of the adapted material.
  10. **Modifications:** Wolters Kluwer Health, Inc. material is not permitted to be modified or adapted without written approval from Wolters Kluwer Health, Inc. with the exception of text size or color. The adaptation should be credited as follows: Adapted with permission from Wolters Kluwer Health, Inc.: [the author(s), title of book, edition, copyright holder, year of publication] or [the author(s), titles of article, title of journal, volume number, issue number, inclusive pages and website URL to the journal page].
  11. **Full Text Articles:** Republication of full articles in English is prohibited.
  12. **Branding and Marketing:** No drug name, trade name, drug logo, or trade logo can be included on the same page as material borrowed from *Diseases of the Colon & Rectum*, *Plastic Reconstructive Surgery*, *Obstetrics & Gynecology (The Green Journal)*, *Critical Care Medicine*, *Pediatric Critical Care Medicine*, *the American Heart Association publications* and *the American Academy of Neurology publications*.
  13. **Open Access:** Unless you are publishing content under the same Creative Commons license, the following statement must be added when reprinting material in Open Access journals: "The Creative Commons license does not apply to this content. Use of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact [permissions@lww.com](mailto:permissions@lww.com) for further information."
  14. **Translations:** The following disclaimer must appear on all translated copies: Wolters Kluwer Health, Inc. and its Societies take no responsibility for the accuracy of the translation from the published English original and are not liable for any errors which may occur.
  15. **Published Ahead of Print (PAP):** Articles in the PAP stage of publication can be cited using the online publication date and the unique DOI number.
    - i. Disclaimer: Articles appearing in the PAP section have been peer-reviewed and accepted for publication in the relevant journal and posted online before print publication. Articles appearing as PAP may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in manuscripts will be made at the time of print publication and will be reflected in the final electronic version of the issue. Accordingly, Wolters Kluwer Health, Inc., the editors, authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.
  16. **Termination of Contract:** Wolters Kluwer Health, Inc. must be notified within 90 days of the original license date if you opt not to use the requested material.

17. **Waived Permission Fee:** Permission fees that have been waived are not subject to future waivers, including similar requests or renewing a license.
18. **Contingent on payment:** You may exercise these rights licensed immediately upon issuance of the license, however until full payment is received either by the publisher or our authorized vendor, this license is not valid. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of Wolters Kluwer Health, Inc.'s other billing and payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.
19. **STM Signatories Only:** Any permission granted for a particular edition will apply to subsequent editions and for editions in other languages, provided such editions are for the work as a whole in situ and do not involve the separate exploitation of the permitted illustrations or excerpts. Please view: [STM Permissions Guidelines](#)
20. **Warranties and Obligations:** LICENSOR further represents and warrants that, to the best of its knowledge and belief, LICENSEE's contemplated use of the Content as represented to LICENSOR does not infringe any valid rights to any third party.
21. **Breach:** If LICENSEE fails to comply with any provisions of this agreement, LICENSOR may serve written notice of breach of LICENSEE and, unless such breach is fully cured within fifteen (15) days from the receipt of notice by LICENSEE, LICENSOR may thereupon, at its option, serve notice of cancellation on LICENSEE, whereupon this Agreement shall immediately terminate.
22. **Assignment:** License conveyed hereunder by the LICENSOR shall not be assigned or granted in any manner conveyed to any third party by the LICENSEE without the consent in writing to the LICENSOR.
23. **Governing Law:** The laws of The State of New York shall govern interpretation of this Agreement and all rights and liabilities arising hereunder.
24. **Unlawful:** If any provision of this Agreement shall be found unlawful or otherwise legally unenforceable, all other conditions and provisions of this Agreement shall remain in full force and effect.

#### **For Copyright Clearance Center / RightsLink Only:**

1. **Service Description for Content Services:** Subject to these terms of use, any terms set forth on the particular order, and payment of the applicable fee, you may make the following uses of the ordered materials:
  - i. **Content Rental:** You may access and view a single electronic copy of the materials ordered for the time period designated at the time the order is placed. Access to the materials will be provided through a dedicated content viewer or other portal, and access will be discontinued upon expiration of the designated time period. An order for Content Rental does not include any rights to print, download, save, create additional copies, to distribute or to reuse in any way the full text or parts of the materials.
  - ii. **Content Purchase:** You may access and download a single electronic copy of the materials ordered. Copies will be provided by email or by such other means as publisher may make available from time to time. An order for Content Purchase does not include any rights to create additional copies or to distribute copies of the materials

#### **Other Terms and Conditions:**

v1.18

Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

## ELSEVIER LICENSE TERMS AND CONDITIONS

May 13, 2019

---

---

This Agreement between Anette Nielsen ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

[License Number](#)

4586620818643

[License date](#)

May 12, 2019

[Licensed Content Publisher](#)

Elsevier

[Licensed Content Publication](#)

CHEST

[Licensed Content Title](#)

Emerging Concepts in the Evaluation of Ventilatory Limitation During Exercise The Exercise Tidal Flow-Volume Loop

[Licensed Content Author](#)

Bruce D. Johnson, Idelle M. Weisman, R. Jorge Zeballos, Ken C. Beck

[Licensed Content Date](#)

Aug 1, 1999

[Licensed Content Volume](#)

116

[Licensed Content Issue](#)

2

[Licensed Content Pages](#)

16

[Start Page](#)

488

[End Page](#)

503

[Type of Use](#)

reuse in a thesis/dissertation

[Portion](#)

figures/tables/illustrations

[Number of figures/tables/illustrations](#)

1

[Format](#)

both print and electronic

[Are you the author of this Elsevier article?](#)

No

[Will you be translating?](#)

No

[Original figure numbers](#)

Figure 4

Title of your thesis/dissertation

Changes in breathing reserve and expiratory flow limitation at peak exercise intensity after a 10-weeks exercise intervention in adolescents with asthma

Publisher of new work

University of Oslo

Expected completion date

May 2019

Estimated size (number of pages)

1

Requestor Location

Anette Nielsen

\*\*\*\*\*

Oslo, other

Norway

Attn:

Publisher Tax ID

GB 494 6272 12

Total

0.00 USD

Terms and Conditions

## INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

## GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. **Reservation of Rights:** Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.
8. **License Contingent Upon Payment:** While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.
9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.
10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.
11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.
12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.
14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

#### **LIMITED LICENSE**

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights. If you licensed translation rights you

may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

**16. Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com> . All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

**17. For journal authors:** the following clauses are applicable in addition to the above:

**Preprints:**

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
  - directly by providing copies to their students or to research collaborators for their personal use
  - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement



- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

**18. For book authors** the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

**19. Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

#### **Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

#### **Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

## 20. Other Conditions:

v1.9

Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

---

---